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Inspite of tremendous advancement made in the field of medical sciences, the 
cure of cancer remains an uphill task. Moreover the rising incidence of its occurrence has 
worsened situation in more awful manner. One in every twelve men and one in every 
twelve women up to 64 years of age are expected to be inflicted by one or other form of 
cancer in their lifetime. The available chemotherapeutic agents are specific and effective 
against limited forms of the cancer. Moreover toxicity constraint and inability to 
eliminate cancer completely are some major factors that restrict their usage. Various lines 
of evidences have shown link between cancer and immune system. Components of 
immune system are capable of recognizing cancerous cells and supplement chemotherapy 
that ultimately leads to tumour regression. 
Keeping in view the fact that most of the anticancer drugs are not successful in 
eliminating cancer and are toxic at higher dose. It can be speculated that while specific 
targeting of these drugs may result in better efficacy with minimal side effects, however 
if combined with immunomodulators can offer a promising strategy to eliminate cancer. 
In the present study we have evaluated antitumorogenic potential of tuftsin bearing 
etoposide liposome against soft tissue sarcoma in swiss albino mice. The formulation was 
found to be more effective than free as well liposomised form of etoposide that was 
devoid of tuftsin. The efficacy of the formulation was evaluated on the basis of 
histopathological examinations and survival rate. 
In other set of experiment we evaluated antigenotoxic effect of imunomodulator 
tuftsin against cyclophosphamide-induced genotoxicity. The result of the study 
demonstrated that treatment with tuftsin alleviate cycophosphamide induced genotoxic 
manifestation on the basis of chromosomal aberration frequency pattern. Tuftsin also 
protects immune cells from toxic effect of cyclophosphamide by increasing their 
proliferation and minimizing chromosomal disorganization. 
Finally, on the basis of data obtained in the present study, we conclude that 
tuftsin augment the activi(> of etoposide and its combination with later offers a novel 
strategy for the treatment of cancer. On the other hand antimutagenic effect shown by 
tuftsin against cyclophosphamide induced genotoxicity led us to conclude that beside 
anticancer activity tuftsin can also play key role in alleviating mutagenesis induced by 
most of the carcinogen. 
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Cancer is a word that refers to approximately 150 diseases that exhibit two characteristics 
in common: (1) an uncontrolled growth of cells and (2) the ability to invade and damage 
normal tissues either locally or at distant sites in the body. Cancer incidence is rising are 
expected to get some or other form of cancer in their lifetime. Cancer occurs when the 
DNA present in a gene is altered in such a way that the gene can no longer instruct the 
cell to produce specific proteins in the normal manner. Such alterations take place when a 
gene is exposed to radiation or particular drugs or chemicals that bring about damage 
DNA within agene ensued by its breaking and incorrect recombination., ultimately 
leading to various mutations. These factors may not only transform normal gene into 
oncogenes, but also inactivate antioncogenes leading to full blown tumour. 
It is indisputable that some degree of immune response against cancer exists in animals 
and humans. Components of the immune system that are capable of recognizing cancer 
cells have been identified in patients with certain cancers. In the laboratory, cells of the 
immune system can kill tumor cells. Even more convincing are clinical results showing 
that stimulation of the immune system with bacterial products or components of the 
immune system itself can lead to tumor regression in some patients. The link between 
cancer and the immune system is also suggested by the fact that people with an impaired 
immune system, such as AIDS patients, are more likely to develop certain cancers, 
including Kaposi's sarcoma, rectal cancer and some specific types of lymphomas 
(Kiesslinge^^/, 1999). 
1.1 Immune response modifiers 
These are substances, either extrinsic or intrinsic to the body, that affect the immune 
response. One group of extrinsic modifiers is referred to as immune potentiators. These 
include BCG, Corynebacterium parvum and endotoxin, which are all microbes or 
microbial products that have been shown to modify the immune response and, under 
certain conditions, to cause tumors to regress or grow more slowly than usual. The 
intrinsic group, known as biological response modifiers, includes interleukin-1 and 
interleukin-2, interferon (alpha, beta, and gamma), tumor necrosis factor (TNF), B-cell 
growth factors and hematopoietic growth factors (such as colony-stimulating factors). 
These agents exert their influence at different stages of the immune response. (Daemen et 
al, 1986) 
The interleukins activate the body's own lymphocytes to do their work. For example, IL-2 
has been found to be effective in some patients with melanoma or with renal cancer when 
it is administered alone or with a patient's own lymphocytes that have been treated with 
IL-2 outside the body (Maass et al, 1995). 
The interferons act on the immune system by stimulating both T cells and macrophages. 
They also prevent cells from multiplying. Scientists believe that these two properties 
together enable interferon to fight some ttmiors effectively. Alpha interferon was the first 
FDA-approved biological response modifier for the treatment of cancer (it is effective 
against a rare form of leukemia) (Kiessling et al, 1999). 
Tumor necrosis factor directly attacks and kills tumor cells. Currently, it is being 
tested alone as in conjunction with gamma interferon to determine its potential efficacy in 
the treatment of human cancers. B-cell growth factors stimulate the multiplication of 
antibody-producing cells. The hematopoietic growth factors step up the production of 
both red and white blood cells in the bone marrow, thereby giving the body additional 
ammunition to fight disease and protect itself against the suppressive effects on the bone 
marrow of radiation and chemotherapy. (Old and Chen, 1998) 
1.2 Activation of macrophages 
The macrophages are involved in many different processes such as tissue remodeling 
during embryogenesis, wound repair, removal of damaged or senescent cells subsequent 
to injury or infection, haemopoiesis and homeostasis. Another function of macrophages is 
to provide a defense line against microbial invasion and to recognize and kill tumor cells. 
Macrophages can accomplish this in a direct manner, involving the release of products 
such as oxygen radicals and tumor necrosis factor that are harmful to microorganisms or 
cancer cells. On the other hand, they play an indirect role in such anti-microbial or anti-
tumor activities by secretion of cytokines or by antigen processing and presentation, 
thereby regulating the immune system. In contrast to macrophage involvement in 
constitutive processes, macrophage participation in host defense against tumor cells 
requires activation signals. Activation of macrophages proceeds via different stages 
accompanied by gradual changes in macrophage properties. Based on the differences in 
capacities and functions, macrophages can be characterized as unstimulated, primed and 
fully activated macrophages (MacKay et al, 1986). Each stage is accompanied by specific 
expression of membranous and secreted proteins, which can be down- or up-regulated 
when macrophages develop into another activation state. Changes in protein expression 
often correlate with the functional ability. For example, for antigen presentation to T-
cells, macrophages are dependent on MHC class II molecules. These molecules are lowly 
expressed on unstimulated macrophages, but are highly expressed on primed, and to a 
lesser extent on activated macrophages. Hence, antigen presentation is maximal in the 
primed state. Similar correlations are found for the release of proteins responsible for 
tumor cell killing, such as TNF (Adams et al, 1992). Since macrophage activation is 
regulated by both inductive and suppressive signals, activated macrophages can switch 
from the activated state to the responsive state. One can distinguish two major categories 
of biological response modifiers that are able to activate macrophages to tumor 
cytotoxicity. 
1.2.1 Bacterial cell wall constituents 
First of all, macrophages can be activated to tumor cytotoxicity by components and 
products of microorganisms. Lipopolysaccharide (LPS), a component of the outer 
membrane of gram-negative bacteria, is one of the most potent activators of macrophages 
and monocytes. However, in vivo LPS may cause harmful effects such as hypotension, 
fever, disseminated blood clotting and even lethal shock (Rietschel et al, 1992). 
The mechanism by which LPS is able to activate macrophages is not fully understood, 
but there is evidence that in plasma a protein referred to as LPS-binding protein binds to 
LPS. The LPS-LPS-binding protein complex is able to bind to CD14, which is expressed 
on the surface of macrophages (Wright et al, 1990). Binding to CD14 and possibly of 
additional surface molecules is followed by signal transduction, which subsequently may 
lead to the activation of LPS-depcndent genes (Wright et al, 1990). Until recently little 
was known on how the LPS signal is transduced across the plasma membrane as CD 14 
lacks an intracellular signaling domain and therefore probably does not trigger 
intracellular signaling directly. Several groups demonstrated that members of the Toll-
like receptor family, which resemble the IL-1 receptor family (Medzhitov et al, 1997), 
play a role in this phenomenon. Of the Toll-like receptor family, especially the Toll-like 
Receptor 2 seems to support an important role in the macrophage responsiveness to 
bacterial LPS (Kirschning et al, 1998; Yang et al, 1999). Analogues of lipid A, such as 
monophosphoryl lipid A, are less toxic than the parent molecule but have also numerous 
effects on macrophages, such as induction of TNF- a IFN- y and induction of nitric oxide 
synthase (NOS), etc. However, the less toxic analogues of LPS and lipid A are in general 
less potent in activating macrophages than the parent compounds (Hattori et al, 1995; 
Kienerera/, 1988). 
The cell wall of gram-positive bacteria does not contain LPS, but instead contains 
peptidoglyeans that have properties similar to those of LPS. Muramyldipeptide {N-
acetylmuramyl-alanyl-isoglutamine) of mycobacterium has been shown to be the 
minimal structural entity of the cell wall capable of inducing adjuvant activity, 
modification of non-specific resistance to infections and tumors and activation of 
macrophages (Daemen et al, 1986). Many analogues and derivatives of 
muramyldipeptide have been synthesized for potential clinical use such as murabutide 
(Darcissac et al, 1996) and the lipophilic derivative muramyltripeptide 
phosphatidylethanolamine (MTP-PE) (Barratt et al 1994; Hoedemakers 1993). The 
effects of muramylpeptides but also those of LPS and its derivatives on macrophages 
include upregulation of cytokine production (TNF a, IFN-y, interleukin-1 (IL-1)), 
expression of inducible NOS (iNOS), nitric oxide (NO) secretion, as well as adhesion 
molecules. All these processes can lead, directly or indirectly, to increased cytotoxicity of 
the macrophages. 
In contrast to LPS, muramyldipeptide and MTP-PE can be injected safely in vivo. 
However, muramyldipeptide, due to its low molecular weight and water solubility, has 
the disadvantage of being rapidly excreted from the body without exerting an 
immunotherapeutic effect. When incorporated into particulate drug carriers, the retention 
time in vivo of both muramyldipeptide and MTP-PE is significantly prolonged (Fogler et 
al, 1985). A major advantage of using such drug carriers to incorporate macrophage-
activating compounds is that, after i.v. or i.p. injection, the drug, together with the carrier, 
is primarily taken up by macrophages (Fogler et al, 1985).The macrophage activating 
agents are thus passively targeted to the macrophages. 
1.2.2 Macrophage activating cytokines 
The second category of macrophage activating agents are cytokines. Macrophage 
activating cytokines predominantly produced by activated T-lymphocytes are generally 
referred to as macrophage activating factors which include IFN- y, granulocyte-
macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating 
factor (M-CSF) as the most important ones. The activation of macrophages by these 
cytokines requires the binding of the cytokine to a receptor on the surface of the 
macrophages which will subsequently lead to the activation of an intracellular signaling 
pathway (Yagisawa et al, 1999) and ultimately leading to modulation of the macrophage 
function. 
IFN- Y has been studied extensively as an activator of macrophage functions (Drapier et 
al, 1988; Green et al, 1992). Incubation of macrophages with IFN- y enhances the 
respiratory burst, the NO secretion, IL-1 secretion and anti-tumor cytotoxic activity. In 
addition, IFN- y enhances receptors and cell surface markers such as adhesion molecules 
and major histocompatibility complex (MHC) class II antigens (Cavaillon et al, 1994). 
GM-CSF induces proliferation of granulocyte and monocyte precursor cells (Ulich et al, 
1990), while M-CSF controls the proliferation of monocyte/macrophage precursors and 
differentiation of monocytes. Both agents effect macrophage functions, which ultimately 
can lead to tumoricidal activity. Both GM-CSF and M-CSF increase the cytokine 
production of macrophages and antibody-dependent cellular cytotoxicity (ADCC). In 
addition, GM-CSF augments the expression of adhesion molecules, respiratory burst and 
the phagocytotic capacity. 
Depending on the way of administration and nature of cytokine, the half-life varies from 
20 min to 1 h after i.v. administration and is prolonged for several hours after s.c. 
administration (Hovgaard et al, 1992).Comparable with bacterial compounds, cytokines 
have also been incorporated into drug carriers, resulting in a 10-20-fold prolongation of 
plasma half-lives compared to soluble cytokines (Kedar et al, 1997). 
In summary, both bacterial cell wall components as well as certain cytokines can activate 
monocytes and macrophages to tumor c>totoxicity. Although several effects on 
macrophage activation are similar between cell wall components and cytokines, also 
differences in activation patterns between both groups of agents are observed. For 
example, induction of nitrogen oxide intermediates is mainly observed by bacterial cell 
wall components while, on the other hand, some cytokines augment for instance antibody 
dependent cellular cytotoxicity. These differences in effects are caused by the differences 
in receptors bound by these agents leading to activation of different signal-transduction 
pathways. 
1.3 Mechanisms of tumor cell killing 
1.3.1 Tumor cell recognition 
Activated macrophages that are able to recognize, bind and subsequently kill tumor cells, 
can distinguish between tumorigenic and non-tumorigenic cells, indicating that 
differences in cell membrane composition can be responsible for this specific tumor cell 
recognition. Several studies have demonstrated that the difference in the amount of 
phosphatidylserine in the outer membrane leaflet of tumor cells and non-tumorigenic 
cells is one of the factors responsible for specific tumor cell recognition (Utsugi et al, 
1991; Elnemr et al, 2000). Upregulation of the amount of phosphatidylserine in the 
external part of the cell membrane by A^-ethylmaleimide (Elnemr et al, 2000) or by 
addition of exogenous phosphatidylserine analogues leads to recognition and subsequent 
lysis or phagocytosis of tumor cells. In addition, carbohydrate structures present on tumor 
cells are also recognized by macrophages (Ichii et al 2000) indicating that altered 
glycosylation of cell surface molecules of tumor cells might be another mechanism for 
tumor cell recognition by macrophages. Some tumor antigens such as carcinoembryonic 
antigen (CEA) and Tn antigen (both human carcinoma-associated antigens) are 
carbohydrate structures. These carbohydrate moities bind to the lectin-like receptors 
present on macrophages (Suzuki et al, 1996). 
Destruction of tumor cells in which macrophages are directly involved is thought to occur 
by two distinct mechanisms, i.e. (1) macrophage-mediated tumor cytotoxicity and (2) 
ADCC. 
1.3.2 Macrophage-mediated tumor cytotoxicity 
Macrophage-mediated tumor cytotoxicity is a slow, cell-to-cell contact-dependent 
process requiring 1-3 days. The susceptibility to macrophage-mediated tumor 
cytotoxicity varies greatly among different tumor cells (Daemen et al, 1989). 
Heterogeneity in intercellular adhesion molecule-1 (ICAM-1) expression may underlie 
these differences. Involvement of cellular ICAM-1 in macrophage-mediated tumor 
cytotoxicity is confirmed by the following observations: 
(1) Decreased binding of macrophage-mediated tumor cytotoxicity-resistant tumor 
cells to monocytes coincided with lower levels of ICAM-1 (Jonjic et al, 1992); 
(2) Enhancement of ICAM-1 expression induced by cytokines resulted in increased 
vulnerability to tumoricidal macrophages, indicating that CD 18/CD11-ICAM-1 
adhesion between effector and target cells plays an important role in macrophage-
mediated tumor cytotoxicity (Darcissac e/a/, 1996); 
(3) Anti-ICAM-1 or anti-CD 18 antibodies caused substantial inhibition of 
tumoricidal activity of monocytes (Bemasconi et al, 1991;). Besides differences 
in expression of adhesion molecules, also the cell cycle stage of the tumor cells 
may play a role in the susceptibility to lysis by tumoricidal monocytes. Horn et al, 
1991 demonstrated that tumor cells leaving the cell cycle going into the quiescent 
state (Go) were no longer susceptible to lysis by monocytes. During coculture of 
monocytes with timior cells, tumor cells can be driven into Go phase by mediators 
released by activated monocj^es. On the other hand, it was found that growth 
stimulatory signals such as epidermal growth factor, increased susceptibility to 
macrophage-mediated tumor cytotoxicity (Bosch et al, 1992). 
1.3.3 Antibody-dependent cellular cytotoxicity 
Both macrophages and monocytes are able to lyse tumor cells by ADCC. ADCC involves 
the recognition and binding of antibody-coated target cells via the Fc receptor on the 
effector cells (Kawase et al, 1985). In this process the Fc region of the cell-bound 
antibody provides an essential link between the effector and target cells necessary for 
intimate cell-to-cell contact and interaction. Upon occupancy and cross-linking of the Fc 
receptor, secretion of mediators involved in tumor cell killing occurs. The 
immunoglobulin classes IgGl, IgG2a, IgG2b, IgG3 have been demonstrated to be 
involved in ADCC (Kawase et al, 1985; Qi et al, 1995). The process of ADCC can be 
completed either rapidly within a few hours or slowly, requiring 1-2 days depending on 
the activation state of the macrophage (responsive, primed or fully activated) and the 
antibody-isotype (Feaietal, 1991). 
The mechanism by which target cells are killed during ADCC probably involves the 
generation of reactive oxygen species, including hydrogen peroxide and superoxide 
(Johnson et al, 1986). In addition, the release of TNF-a and IL-1, proteases and 
complement components may play a role in the lysis of the target cell. Murm and Cheung 
demonstrated that human macrophage-derived monocytes cultured with M-CSF were 
able to efficiently kill several types of antibody-coated tumor cells by phagocytosis. 
Phagocytosis was also observed in macrophage-mediated tumor cytotoxicity by (Gardner 
et al, 1991) who demonstrated by electron microscopy that tumor cells can be taken up 
by Kupffer cells. 
In summary, tumor cells can be killed by macrophages either by macrophage-mediated 
tumor cytotoxicity or ADCC. In macrophage-mediated tumor cytotoxicity, adhesion 
molecules such as ICAM-1 play an important role in the interaction between tumor cells 
and macrophages, while in ADCC the presence of antibodies that recognize tumor 
antigens are needed. Both processes will end up in the release of cytotoxic mediators 
including TNF- a, IL-1, NO and reactive oxygen intermediates or phagocytosis. 
1.4 Mediators in tumor cell killing 
1.4.1 Tumor necrosis factor 
The relative importance of mediators involved in tumor cell killing depends on the 
intrinsic susceptibility of different tumor cells as well as on the activation conditions of 
the effector cells. TNF, produced by activated macrophages, is known as a soluble 
protein (17 kDa) but also as a membrane-associated precursor molecule (26 kDa) (Jeong 
et al, 1997). After cleavage of the precursor molecule, the soluble form of TNF is 
secreted as a homotrimeric protein. Both the membrane-associated and the soluble 
molecules are effective in target cell killing (Marr et al, 1997). The mechanism by which 
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TNF is able to kill target cells involves the binding of TNF to TNF-receptors. Two 
distinct TNF receptors, which are present on the majority of cell types and tissues have 
been described, and are known as TNF receptors type 1 and 2 (TNF-Rl, TNF-R2) 
(Hohmann et al, 1990). Probably, TNF-R2 is biologically less relevant than TNF-Rl, as, 
in contrast to TNF-Rl, binding of TNF to TNF-R2 is not sufficient to initiate cell killing. 
Binding to TNF-Rl can induce cytotoxicity, anti-viral activity, fibroblast proliferation, 
and induction of NF-KB. Binding to TNF-R2 induces thymocyte and cytotoxic T-
lymphocyte proliferation (Tartaglia et al, 1993). After binding of TNF to its receptor, the 
receptor-TNF complex is internalized by receptor-mediated endocytosis, followed by the 
induction of multiple intracellular pathways. Among the effects reported are the 
generation of reactive oxygen intermediates in mitochondria preceding plasma membrane 
permeabilization, induction of iNOS-expression, DNA strand breaks and induction of 
serine proteolytic activity (Suffys et al, 1988). Ultimately, these processes can lead to cell 
death. (Sveinbjomsson et al, 1997). Recently, also other members of the TNF family i.e. 
TNF-related apoptosis-inducing ligand (TRAIL) and Fas-ligand (FasL) have shown to be 
involved in cell death. Both ligands are expressed on the cell surface on monocj^es or 
macrophages and induce apoptosis in cells expressing the receptor for TRAIL or FasL 
subsequent to the interaction between ligand and receptor (Griffith et al, 1999; Kiener et 
al, 1997). However, the role of these mediators in tumoricidal activity of monocytes or 
macrophages has to be elucidated. 
1.4.2 Nitric oxide 
NO produced by macrophages is synthesized enzymatically from -arginine by nitric 
oxide synthase (NOS). NOS exists as a constitutive and as an inducible enzyme. 
Macrophages contain the inducible type of NOS, i.e. iNOS, which is found upon 
exposure to cytokines and bacterial cell wall products (Kroncke et al, 1995) under strict 
anaerobic conditions NO is stable but in the presence of oxygen NO is oxidized to higher 
nitrogen oxides, such as peroxynitrite (Xia). The end products are nitrite and nitrate. 
The toxic effects of NO and its derivatives on target cells are due to several mechanisms 
First, NO mediates loss of iron from cells thereby inactivating iron-sulfur cluster-
containing enzymes such as the citric acid cycle enzyme aconitase, NADH-ubiquinone 
oxidoreductase and succinate-ubiquinone oxidoreductase of the mitochondrial electron 
transport (Henry et al, 1993). Second, NO is capable of inducing zinc release from zinc-
containing proteins thereby inducing disulfide formation. This disulfide formation 
inhibits DNA-binding activity of zinc finger type transcription factors (Kroncke et al, 
1994). Third, NO is capable of influencing the activity of ion channels thereby destroying 
the mitochondrial membrane potential (Richter et al, 1994). 
Although the role of NO in the anti-tumor effect of rodent macrophages is well 
established (Takao et al, 1996). Its role in anti-tumor cytotoxicity in humans remains 
controversial. Several groups demonstrated NO secretion by human monocytes 
(Weinberg et al, 1995; Zembala et al, 1994). However, the conditions needed for NOS 
activation in human monocytes are different from those needed for the activation of 
rodent macrophages to secrete NO. Zembala et al. showed that human monocytes 
stimulated with various cytokines such as IFN-y and TNF-a did not induce NO secretion, 
while under the same circumstances rodent peritoneal macrophages released large 
amounts of NO. However, upon coincubation of monocj^es with some tumor cell types, 
NO secretion could be measured (Zembala et al, 1994). NO secretion or secretion of a 
NO metabolite in human cells was substantially lower than in rodent macrophages 
(Albina, 1995). The observation that human and rodent monocytes produce NO under 
different conditions suggests the occurrence of different pathways. 
Taken together, TNF and NO are considered as the most important mediators directly 
involved in tumor cell killing. These mediators are most effective when there is close 
cell-to-cell contact. However, the observation that NO does not play such a prominent 
role in tumor cytotoxicity of human macrophages as is found for rodent macrophages, 
may indicate that also other (yet unknown) mediators must be capable of direct cell 
killing. Candidates are TNF-related ligands such as TRAIL and FasL. 
1.5 Tumor-associated macrophages 
1.5.1 Recruitment of tumor-associated macrophages 
Although it has been established that macrophages are able to infiltrate tumors, the role 
of tumor-associated macrophages in tumor growth is still unclear. Infiltration of 
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macrophages in a tumor varies greatly from 0 to more than 80% of the total cellular 
tumor mass in animal models (Claasen et al, 1992). In general, the percentage of 
macrophages in human tumors is somewhat lower than in animals, ranging from 0 to 
70%, depending on the tumor type (Merogi et al, 1997). There seems to be no or only 
very little correlation between immunogenicity of the tumor and the number of tumor-
associated macrophages in a tumor (Zhang et al, 1997). Tumors sometimes produce 
factors that are likely to be responsible for accumulation of macrophages in the tumors. A 
cytokine with a molecular mass of 12 kDa referred to as monocyte chemotactic protein-1 
(MCP-1), also known as monocyte chemotactic and activating factor, has been described 
to play an important role in attracting macrophages to tumor sites. Recruitment of 
peritumoral macrophages was reported to be independent of MCP-1 production; therefore 
MCP-1 seems responsible for recruitment of intratumoral macrophages only. Additional 
evidence for the involvement of MCP-1 in the recruitment of intratumoral macrophages 
was obtained in a study on the transfer of the MCP-1 gene into murine melanoma cells. 
Subcutaneous and intramuscular tumors induced by these transfected cells contained a 
significantly higher percentage of tumor-associated macrophages than tumors of 
untransfected cells. MCP-1 producing cells grew slower than untransfected cells in mice, 
resulting in a longer survival time. On the other hand, transfection with MCP-1 caused a 
modest but significant increase in tumorigenicity and tumor take rate and resulted in a 
decreased susceptibility to local IL-2 treatment. Similarly, Zhang et al. reported that 
human carcinoma cell lines producing high levels of MCP-1 showed earlier recruitment 
of tumor-associated macrophages while these cells had a lower tumor take rate than low-
or non-producers. In vivo administration of antibodies to MCP-1 inhibited macrophage 
infiltration and stimulated tumor growth. This group also demonstrated that tumor growth 
was delayed or even abolished if at the time of subcutaneous inoculation of tumor cells 
(not producing MCP-1), the chemotactic peptide jV-formyl-methionyl-leucyl-
phenylalanine, was given. Since this peptide has been described to induce early monocyte 
recruitment into tumors these results suggest that at least in this model tumor-associated 
macrophages play a major role in tumor rejection. In addition, the number of intratumoral 
macrophages negatively correlated wdth tumor size (Zhang et al, 1997). 
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In several murine tumor models, however, no correlation was found between the number 
of tumor-associated macrophages and tumor growth rate or metastatic spread (Milas et al, 
1987). In addition to MCP-1, also other chemoattractants such as MCP-2, MCP-3, the 
colony stimulating factors M-CSF and GM-CSF and vascular endothelial cell growth 
factor have been reported to be produced by some tumors (Scholl et al, 1994). 
1.5.2 Tumor-associated macrophages and angiogenesis 
The release by tumor cells of tumor-derived chemotactic factors capable of attracting 
monocytes to the tumor, suggests a favorable effect of the presence of macrophages for 
the tumor. This favorable effect may be explained by the fact that macrophages are 
involved in many processes; angiogenesis is one of them. Several studies reported a 
significant positive correlation among high vascularization of the tumor, increased 
macrophage infiltration and reduced overall survival in patients with breast carcinoma, 
pulmonary adenocarcinoma and endometrial carcinoma (Salvesen et al, 1999). 
The spread and growth of tumor cells is dependent on the formation of new blood vessels 
and thus on angiogenesis. For this process the basement membrane and extracellular 
matrix have to be destroyed, followed by recruitment and/or proliferation of endothelial 
cells. Macrophages are able to promote these processes by 
(1) The secretion of proteolytic enzymes that degrade extracellular matrix 
(Hildenbrand e/a/, 1998). 
(2) The release of growth factors, among which are tumor growth factor-P (TGF-P), 
platelet-derived growth factor, vascular endothelial growth factor (VEGF), and 
TNF-a. The release of these factors plays a key role in angiogenesis. In vitro it 
has been demonstrated that production of the potent angiogenic factors IL-8 and 
VEGF from melanoma cells is upregulated through TNF-a and IL-la secreted by 
activated macrophages (Torisu et al, 2000). Hence, macrophages can also 
indirectly induce the release of angiogenic factors by tumor cells themselves. 
Among the enzymes responsible for destroying the basement membrane and extracellular 
matrix are matrix metalloproteinase-2 (MMP-2, gelatinase A, type IV collagenase) and 
MMP-9 (gelatinase B, type IV collagenase). The degradation of the basement membrane 
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and extracellular matrix provides a microenvironment in which activated endothelial cells 
can proliferate and migrate to form new blood vessels. Increased expression of MMP-2 
and MMP-9 was found in several tumor types. Expression of MMP-2 and MMP-9 by 
host stromal cells, including macrophages, correlated with the depth of tumor invasion 
and histological grade in endometrial carcinoma (lurlaro et al, 1999). 
The angiogenic effects of most substances such as basic fibroblast growth factor, TGF-P, 
IL-8 and VEGF are mainly due to stimulation of migration and mitosis of endothelial 
cells. IL-8, a chemoattractant cytokine produced by several cell types among which are 
macrophages and tumor cells, has been shown to attract and activate neutrophils in 
inflammatory regions and to be angiogenic. IL-8 expression and survival is inversely 
correlated in nude mice inoculated with human ovarian carcinoma and also in patients 
with cervical cancers.VEGF also stimulates macrophage migration and is upregulated in 
macrophages by hypoxia (Fujimoto et al, 2000). In addition, it increases the vascular 
permeability and induces the production of plasminogen activator. 
On the other hand, tumor-associated macrophages are able to directly or indirectly release 
substances, such as interferons, angiostatin, platelet factor-4 and thrombospondins that 
mediate inhibition of tumor and/or their metastases. These Factors inhibit angiogenesis 
by inhibiting endothelial cell proliferation. Angiostatin is formed by cleavage of 
plasminogen by metalloelastase. As metalloelastase is produced by (tumor-associated) 
macrophages, these macrophages seem to be responsible for the production of 
angiostatin. The angiostatin-induced inhibition of cell proliferation is due to an increase 
in apoptotic cells (Claesson-Welsh et al, 1998). 
The role of tumor-associated macrophages in tumor angiogenesis also seems to be 
influenced by the stage of the tumor growth. In the early stages, the presence of timior-
associated macrophages will delay tumor cell proliferation. When the tumor grows 
beyond a size of 1 cm , angiogenesis is thought to be necessary to provide the tumor with 
sufficient blood supply (Dvorak et al, 1986). At that time, tumor-associated macrophages 
may support tumor growth by secretion of angiogenic factors. In addition, the tumor may 
then be able to produce substances, such as prostaglandin E2, that prevent macrophages 
from being tumor cytotoxic. Thus, early recruitment of cytotoxic macrophages may 
prevent outgrowth of tumor cells in cancer patients. 
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Summarized, whether tumor-associated macrophages will secrete tumor cytotoxic 
mediators or tumor growth supporting, i.e. proangiogenic, mediators probably depends 
on: 
(1) The activation state of the macrophages, as is described earlier in this report; 
inhibition of tumor growth due to the presence of macrophages, is mostly observed in 
models in which early after tumor cell inoculation macrophages are recruited (Ushio 
etal, 1996). 
(2) The tumor stage; stimulation of tumor development by tumor-associated 
macrophages is in general observed in established timiors containing 
immunosuppressive tumor-associated macrophages, or tumor-associated 
macrophages that become immunosuppressive during tumor development (Thomas 
etal, 1995). 
(3) Microenvironmental influences, such as macrophage suppressive agents released by 
tumor cells, e.g. TGF-P and prostaglandin E2 (Kambayashi et al, 1995) that are 
known to inhibit various functions of macrophages. 
So, the onset of angiogenesis in tumors is determined by the local balance between pro-
angiogenic and anti-angiogenic substances released by tumor-associated macrophages 
and tumors. The activation state of the macrophages, the tumor stage and 
microenvironmental conditions influence this balance. 
1.6 Antigen presenting cells 
Dendritic cells form a cell population strongly related to the macrophages and are 
'professional' antigen-presenting cells. The primary function of dendritic cells is uptake 
and processing of antigens followed by the presentation of peptides on MHCI or MHCII 
molecules thereby initiating a T-lymphocyte response.Very low dendritic cell-to-T-cell 
ratios (1:50-1:200) suffice to provoke T-cell stimulation. Normally, the amounts of 
specific antigen-MHC complexes on tumor cells are small and the occurrence of being 
recognized by a T-cell clone is rare (Porgado et al, 1995; Bender et al, 1995; Banchereau 
et al, 1998). Dendritic cells provide a means to increase the contact probability between 
T-cells and antigens by capturing (tumor) antigens, process them into peptides and 
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display these in the context of MHC-molecules in the presence of costimulatory 
molecules. 
The expression of surface antigens and the ability to take up and process antigens 
depends on the maturation stage of the dendritic cell. Immature dendritic cells are located 
in the peripheral tissues where they efficiently capture and process antigens. Antigen 
uptake is most efficiently accomplished via mannose-receptor-mediated endocytosis and 
macropinocytosis for taking up receptor-bound particles or large volumes of fluid, 
respectively.The mannose receptor has a broad specificity for sugars as well as 
hydrophobic molecules and therefore has a broad ligand specificity. The mannose 
receptor has the capacity to release the antigen at low pH in intracellular compartments 
and then to recycle to the cell surface.Thus it can deliver amounts of ligand that far 
exceed the number of receptors .Macropinocytosis is a constitutive process in dendritic 
cells and involves a cytoskeleton-dependent vacuole formation by which large vesicles 
(up to 3 i|m) can be phagocytosed .Dendritic cells are able to retain intact proteins for up 
to 2 days before presenting them probably by the presence of retention compartments 
which are mildly acidic macropinosomes containing high concentrations of MHCII 
molecules (Winzler et al, 1997; Pierre et al, 1997). 
Antigen uptake, but also cytokines involved in inflammation such as TNF and IL-1 and 
bacterial products, induce maturation and migration of dendritic cells from the periphery 
to lymph nodes where they present processed antigens to T-lymphocytes. Maturation of 
the dendritic cells may lead to further acidification of the macropinosomes which is 
needed for degradation and processing of the antigens. Maturation of dendritic cells is 
furthermore characterized by the disappearance of intracellular MHCII-rich 
compartments due to transportation of MHCII molecules to the cell surface. In addition, 
the level of macropinocytosis and endocytosis is reduced and expression of MHCI, 
costimulatory and adhesion molecules such as CD40, B7.2, and ICAM-1 (Winzler et al, 
1997) is increased. This process of maturation is consistent with loss of the capacity of 
antigen uptake and processing, while on the other hand, the ability of antigen presentation 
is strongly increased. 
Dendritic cells can be generated in large numbers either from CD34'^  bone marrow cells 
or from peripheral blood monocytes when cultured in vitro in the presence of GM-CSF 
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and TNF or IL-4. GM-CSF is necessary to stimulate proliferation of the precursor 
dendritic cells; IL-4 suppresses the differentiation into monocytes/macrophages, while 
TNF enhances maturation of dendritic cells (Lardon et al, 1997). 
The possibility to culture large numbers of dendritic cells in vitro makes this cell type 
accessible for immunotherapeutic treatment of tumors. In animal studies, bone marrow 
derived dendritic cells pulsed with tumor or viral antigens were capable of inducing 
antigen specific cytotoxic T-cell responses in vivo. In addition, treatment with dendritic 
cells pulsed with well-defined tumor antigens as well as unfractionated acid-eluted tumor 
peptide mixtures protected mice against tumor challenge or suppressed tumor growth 
(Celluzzi er a/, 1996). 
Also human studies have been described in which autologous dendritic cells were pulsed 
with tumor specific peptides. In a clinical trial reported by (Hsu et al, 1996), four patients 
with B-ceil lymphoma were treated with autologous dendritic cells derived from 
peripheral blood monocytes. The patients received two immunizations with dendritic 
cells pulsed with tumor specific peptide i.v. and two immunizations s.c. with soluble 
tumor protein to boost the primary response induced by peptide-loaded dendritic cells. In 
all four patients anti-tumor responses were observed and three patients showed clinical 
responses. 
Several phase I clinical studies have been reported in which melanoma patients were 
intravenously, subcutaneously or intratumorally injected with dendritic cells pulsed with 
tumor specific peptides. The dendritic cells were derived from peripheral blood 
monocytes or hematopoietic progenitor cells. In these studies, immunotherapeutic 
treatment with dendritic cells was well tolerated. Complete regression of tumors was 
observed in 2 of 14, 1 of 16, 4 of 7 and 6 of 11 patients and stable disease was observed 
in 6 of 14 and 2 of 16 patients (Lau et al, 2001). 
A phase II clinical study is described by (Lodge et al, 2000). In this study, 107 prostate 
cancer patients received six infusions of dendritic cells pulsed with peptides derived from 
prostate-specific membrane antigens every 6 weeks. Partial and complete responses were 
observed in 12 and 2 patients, respectively. The clinical responses tended to correlate 
with immunocompetence of the patients, i.e. a positive DTH response and high IFN-y 
production by T-cells maintained throughout treatment. 
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Although dendritic cells are considered as the most important cell type in the generation 
of cytotoxic T-cells, also macrophages are able to stimulate the generation of cytotoxic T-
cells by means of efficient antigen presentation. This means that macrophages have not 
only a non-specific, direct way of tumor cell killing as described earlier, but also a more 
specific and indirect way. An in vitro study of (Toujas et al, 1997) in which 
macrophages are directly compared with dendritic cells in cytotoxic T cell generation, 
showed that dendritic cells and macrophages were comparably effective in the activation 
of anti-melanoma cytotoxic T cell clones, after exogenous loading of melanoma specific 
peptides. (Apostolopoulos et al, 2000) immunized macrophages and dendritic cells ex 
vivo using oxidized marman linked to MUCl to target the mannose receptor and the 
MHC Class I antigen-presenting route. They demonstrated that murine mannose receptor 
bearing macrophages derived from peritoneal exudate cells that were cultured ex vivo 
with oxidized marinan linked to MUCl efficiently present MUCl to T cells leading to the 
generation of CTLs and protection from tumor challenge. 
The results described suggest that immunization strategies using in vitro cultured antigen 
presenting cells pulsed with tumor antigens may be useful in inducing tumor-specific 
cytotoxic T-cell responses in cancer patients. Several clinical studies are ongoing and can 
be expected in the near future. 
1.7 Macrophage activation in immunotherapy of human cancers 
Macrophages/monocytes as a means to eliminate tumor cells. Two strategies can be 
distinguished: 
(1) The in vivo activation of macrophages using biological response modifiers, such 
as MTP-PE, GM-CSF, M-CSF or IFN-
(2) Adoptive cellular immunotherapy, in which effector cells are isolated firom the 
body and are re-infused several days later after in vitro activation of these cells 
Owith biological response modifiers. 
1.7.1 Immunotherapy with biological response modifiers 
In a MTP-PE clinical phase II study, relapsed osteosarcoma patients with pulmonary 
metastases were treated with liposomal MTP-PE. After i.v. infiision of the MTP-PE 
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liposomes, liposomes were found in the liver, spleen, lung and in and around lung 
metastases. While cytokine expression in monocytes was elevated, the expression of 
cytokines in lymphocytes was not influenced. Sixteen patients receiving MTP-PE 
liposomes for 24 weeks showed a prolongation in time to relapse (9.0 months) compared 
to that of a historical group (4.5 months). Liposomal MTP-PE treatment was well 
tolerated, as only mild side effects limited to fever, chills, myalgias and mild fatigue were 
observed (Asano et al, 1993; Kleinerman et al, 1992). 
In a GM-CSF phase I/II study (Nagler et al, 1996), 34 patients with Hodgkin's 
lymphoma, non-Hodgkin's lymphoma, breast cancer or neuroblastoma received GM-CSF 
after autologous bone marrow transplantation. Cytotoxicity, ADCC, expression of the 
activation antigen CD 16, and cytokine production were measured before, during and after 
GM-CSF administration. Within the group receiving GM-CSF, ADCC was higher during 
GM-CSF therapy than in the periods before and after GM-CSF administration. In 
addition, in vivo GM-CSF administration led to elevated levels of endogenous TNFa-
and GM-CSF. Also clinical phase I and II studies have been conducted in which GM-
CSF treatment was combined with other cytokines (such as IL-12 and IL-2) or 
monoclonal antibodies (Ragnhammar et al, 1996). In most studies an enhancement of 
ADCC was reported. Although stable disease was occasionally reported in these studies, 
explicit tumor regression upon GM-CSF administration has not been reported thus far. 
1.7.2 Adoptive cellular Immunotherapy 
The development of leukopheresis and counterflow centrifugal elutriation has largely 
overcome the technical barrier of obtaining large numbers of monocytes needed for 
adoptive transfer in humans. To further improve the yield of isolated monocytes, patients 
have occasionally been pretreated with growth factors to increase the number of 
circulating blood monocytes. After isolation of the monocytes, cells were cultured for 
approximately 7 days to mature into macrophages. After 6 days of culture, biological 
response modifiers such as IFN-y or sometimes MTP-PE or LPS are added to activate the 
macrophages. The subsequent re-infusion of the autologous monocytes into the host has 
been performed locoregionally as well as systemically. Generally, re-infusion of up to 
2.7x10^ (maximal number reported) of the autologous activated monocytes was well 
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tolerated. Low-grade fever was the most common side effect. Other side effects, which 
were usually mild, include malaise, and fatigue in case of i.v. and i.p. administration. In 
addition, a few patients receiving monocytes i.p., also indicated slight peritoneal irritation 
(Hennemann et al, 1998). 
In only three cases in which patients received activated monocytes systemically, 
stable disease was reported. Also in three patients who received activated monocytes i.p., 
stable disease was observed (Eymard et al, 1996).Furthermore, in two patients ascites 
production stopped for approximately 3 months and a normalization of the elevated level 
of the serum tumor marker carcinoembryonic antigen in ascites was observed in one of 
these patients. 
Upon i.p. administration of activated monocytes, the effector cells probably remain in the 
peritoneal cavity (in case of peritoneal cancers also the site of the tumor) for at least 5-7 
days, and do not accumulate in other organs, as shown with indium-Ill ('"in) labeled 
monocytes (Faradji et al, 1991).Since locoregional transfer of effector cells is more 
effective than systemic transfer of cells, accumulation of the monocytes in the peritoneal 
cavity might be essential for the observed therapeutic effect. 
Although clinical responses in terms of measurable regression of tumor growth were 
almost absent, biological responses, such as elevated serum neopterin levels, IL-6 
appearance in sera and ascitic fluids, increase in granulocyte count in blood, increase of 
IL-1, IL-6 and TNF-a in peritoneal fluids were reported in several studies (Andreesen et 
al, 1990; Hermemann et al, 1995; Faradji et al, 1991).In two studies circulating fibrin 
monomers were detected after i.v. administration of monocytes, indicating the induction 
of the coagulation cascade by the macrophages. 
Although in vitro monocyte derived macrophages are more potent in lysing tumor cells 
than freshly isolated monocytes, no significant regression of tumor has been observed 
thus far after adoptive immunotherapy. These results are not unexpected, since all clinical 
studies so far have been phase I or II studies, which focus particularly on the cylotoxicity 
of the treatments rather than on the therapeutic effect. Furthermore, the number of 
patients entered in phase I or II studies are rather small and most patients have large 
established tumors that negatively affects the prognosis. However, locoregional 
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administration of tumoricidal macrophages in patients with progressive tumor in the 
peritoneal cavity might have an inhibiting effect on tumor growth. 
The observation that most immunotherapeutic approaches described above, showed no or 
only minor side effects encourages further efforts to investigate its therapeutic potential 
in the treatment of minimal residual diseases. In case of minimal residual disease 
immunotherapeutic treatment aimed at macrophage activation may be more promising as 
the number of macrophages compared to the number of tumor cells is much larger. 
Furthermore, the use of combinations of macrophage activating mediators (Han et al, 
1999) might improve the results of immunotherapy based macrophage activation. 
1.8 Gene therapy 
In the last decade, tumor cells genetically modified with cytokines, adhesion or MHC 
molecules have been examined for their anti-tumor effects in animal studies. These 
genetic modifications of tumor cells allow the induction of an immune response or 
facilitate tumor cell recognition or tumor cell killing by activated host immune cells. 
(Dranoff e/ al, 1993) investigated the effect of vaccination with both live and irradiated 
tumor cells retrovirally transfected with ten different cytokines, growth factors and 
adhesion molecules in a murine BI6 melanoma model. They showed that transfection 
with the GM-CSF gene resulted in the best anti-tumor effect. The effect was ascribed to a 
potent, specific and long-lasting anti-tumor response. These results are supported by 
other murine studies, which also demonstrated protection to tumor challenges upon 
vaccination with GM-CSF transduced tumor cells (Mahvi et al, 1996). Sanda et al, 1994 
vaccinated rats with GM-CSF secreting prostate tumor cells several days after tumor 
inoculation. A significant increase in the number of rats remaining tumor-free were 
observed when compared to the non-treated group and the group treated with non-
transduced tumor cells with soluble GM-CSF. 
Dow et al, 1998 reported on the successful treatment of canine melanoma by in vivo 
transfection with the GM-CSF gene. The 26 dogs that entered into the study had a 
histologic confirmation of spontaneously developed melanoma. The dogs were treated 
every 2 weeks for at least 12 weeks with intratumoral and peri tumoral injections with 
lipid-complexed plasmid DNA encoding GM-CSF and staphylococcal enterotoxin B as a 
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superantigen. The therapy was well tolerated and 46% of the dogs showed complete or 
partial remission (best responses in animals with small tumors). Histological examination 
of the tumors showed that there was a strong increase in the number of infiltrated T-
lymphocytes and macrophages compared to tumors injected with liposome-complexed 
empty DNA plasmid. In addition, there was a strong correlation between tumor 
regression and high levels of CTL response detected in peripheral blood Iymphoc)^es. 
As GM-CSF is known to stimulate macrophages and dendritic cells to enhance antigen 
presentation to T-cells, GM-CSF secretion is probably involved in the initiation of CTL 
induction. In most of the studies using tumor cells transfected with the GM-CSF gene, a 
strong increase in the number of antigen presenting cells (macrophages and/or dendritic 
cells), and CD4^ and CD8^ T-cells in the tumor were found (Soiffer et al, 1998;) 
observation strongly suggests the involvement of these cells in the induction of systemic 
immune responses and tumor regression. Another mechanism of suppression of tumor 
metastases by GM-CSF secreting tumor cells has been described by Dong et al, 1998. 
They inoculated syngeneic mice and nude mice with B16-F10 or K-1735 melanoma cells 
engineered to produce high amounts of GM-CSF (>1 ng/10^ cells) s.c. and observed 
slow-growing tumors in these animals. In addition, these tumor cells suppressed lung 
metastases of Lewis lung carcinoma, UV-2237 fibrosarcoma, K1735 and B16-F10 tumor 
cells not producing GM-CSF. The production of GM-CSF directly correlated with 
infiltrating macrophages and with their metalloelastase activity. As discussed above, 
metalloelastase can cleave plasminogen into angiostatin that is a potent inhibitor of 
angiogenesis by inhibiting the proliferation of endothelial cells. Thus, GM-CSF produced 
by tumor cells can upregulate metalloelastase in tumor-associated macrophages which 
leads to production of angiostatin and, hence, growth suppression of tumors and distant 
metastases. 
Although most studies describe gene transfection with the GM-CSF gene, also 
other genes affecting the macrophage population have been used in experimental cancer 
gene therapy. Inoculation of mice with Lewis lung carcinoma cells retrovirally 
transfected with M-CSF resulted in an enhanced survival of the animals and prevention 
of lung metastases (Dong et al, 1999) Increasing the amount of M-CSF secreted, 
increased the survival rate. Furthermore, both vaccinations with M-CSF transfected 
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Lewis lung carcinoma cells before and after inoculation of the parental cells, significantly 
prolonged the survival of the mice. Similar results were found by Kimura et al, 1996, 
who observed prolonged survival in mice inoculated with M-CSF transfected L1210 
mouse lymphoid cell line. 
Dong et al, 1999 reported on a study in which highly metastatic PC-3M human 
prostate cancer cells transfected with the IFN-P gene were injected s.c. or into the 
prostate of nude mice. While rapidly growing tumors and regional lymph node 
metastases were observed in mice injected with the parental cells, no tumor growth and 
metastases were found in mice injected with IFN-P producing PC-3M ceils. IFN-P 
secreting tumor cells were also able to suppress tumor growth of bystander non-
transduced tumor cells. Immunohistochemical analysis revealed that IFN-P transfected 
PC-3M tumor cells were heavily infiltrated with macrophages in contrast to the parental 
tumor cells. In T and NK-cell compromised animals injected with IFN-P transfected PC-
3M cells, only small avascularized tumors were present, in contrast to tumors of animals 
injected with parental PC-3M cells or cells transfected v^th a control vector. These 
results indicate that inhibition of vascularization and the infiltration of macrophages due 
to the production of IFN-p are responsible for tumor growth inhibition. 
Besides animal studies, also human clinical phase I gene therapy studies have been 
described (Soiffer et al, 1998; Simons et al, 1997). Simons et al, 1997 immunized 18 
patients suffering from renal cell carcinoma with irradiated autologous GM-CSF 
transfected renal cell carcinoma cells. To evaluate the cell-mediated immunity, a delayed-
type-hypersensitivity assay was performed before and after treatment. The therapy was 
well tolerated, and one patient, who displayed the largest delayed-type-hypersensitivity 
response, showed an objective partial response (reduction of pulmonary metastases). 
Injection sites i.d. and s.c. were strongly infiltrated with antigen presenting cells and T-
lymphocytes. 
Similar results were observed in a study with 21 melanoma patients who were treated 
with irradiated autologous melanoma cells transduced with the GM-CSF gene (Soiffer et 
al, 1998). Also high infiltration of antigen presenting cells and T-lymphocytes and 
extensive tumor cell destruction was observed upon vaccination with the GM-CSF 
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transfected tumor cells. One partial response, one mixed response and three minor 
responses were observed. 
As clinical phase I studies aim at evaluation of safety and toxicity with increasing doses 
of treatment rather than therapeutic effects, these studies are often performed in patients 
with advanced tumor disease not amendable to standard therapy. Therefore, as the 
prognosis in these patients is often bad and the number of patients small, clinical 
responses are generally rare in phase I studies. 
Taken together, the results in animal as well as in human studies indicate that this kind of 
immune/gene therapy can enhance the host immune response towards tumor cells. 
Antigen presenting cells, consisting of macrophages and dendritic cells, together with T-
lymphocytes appear to be involved in this process. Additional clinical studies will have to 
be conducted to elucidate the effectiveness of immune/gene therapy. 
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PAIZTII 
OSOMES 
Liposomes are vesicular structures of colloidal nature assembled when 
amphipathic lipids are dispersed in water. The vesicular structures can be thought of as 
artificial lipid bilayer membranes enclosing aqueous inner core. These were first 
described by Alec D. Bangham in 1965 (Bangham et al, 1965), and initially used as 
models for studying dynamic properties such as fluidity, phase transitions etc. of 
biomembranes. However, potential of these vesicles was soon realized as versatile 
models, reagents and tools in various scientific disciplines including, biology, 
biochemistry, and biophysics (Table 1). 
Various liposome-based formulations that have been developed rely on their 
composition, colloidal, chemical, microencapsulating and surface properties. The 
applications of the liposomes range from their use as drug delivery systems 
(antimicrobial / tumor drugs etc.), vaccines, cosmetic formulations (skin care products, 
shampoos), diagnostics, ecological cleansing modules, and food preparations to novel 
breakthroughs like gene and enzyme therapy. 
2.1 Composition 
Liposomes resemble cellular biomembranes in being composed of 
amphiphiles such as phospholipids and sphingolipids, which upon their exposure to 
aqueous environment, tend to self-organize to form ordered structures. The assemblage of 
amphipathic molecules to the vesicular entities minimizes the chances of interaction of 
hydrophobic moieties with surrounding water molecules. 
A carefril examination at the process of self-organization in amphiphilic molecules 
reveals that there may be three geometric factors that determine the nature and sizes of 
the vesicles viz. 
• Area of the molecule -(A) 
• Volume of their hydrocarbon chain -(V) 
• Maximum length of the chains -(L) 
The crucial combination of these parameters is geometrically the packing parameter, I, 
such that 
i= (V/A*L). 
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• If the value of i is < 1/3 then spherical micelles form. 
• If 1/2 < (i) < 1 then bilayers are formed. 
In fact, the molecules that form bilayers are mainly those with large hydrocarbon 
chains, which are too bulky to fit into smaller molecular assemblies like micelles. A 
quick look at the values of (V/A*L) for different structures shows that for the same head-
group and maximum length of the chains, molecules with double the volume of the 
hydrocarbon chain form bilayers. Thus molecules with two hydrocarbon chains are likely 
to form bilayers. The most important class of bilayer forming molecules is phospholipids. 
It becomes energetically favorable for the bilayer to form closed spherical structures 
rather than very long planar structures. These closed spherical bilayers are called vesicles 
or liposomes. If (V/A*L) > 1 then usually inverted micellar structures are formed or the 
molecules precipitate out of the solution (e.g. cholesterol). Vesicles (unilamellar - single 
bilayer) are a Particular case from the family of spherically concentric multilamellar 
(many bilayers) structures called liposomes. 
The properties are also influenced by external parameters like the temperature and 
the presence of certain molecules nearby. The presence of proteins in the biological 
membranes influences their properties e.g. improves the mechanical properties. The best-
characterized liposomes are those with lipids having packing parameter close to 1.0. The 
lipid classes include phosphatidylcholine, phosphatidylserine, phosphatidylinositol, 
sphingomyelin, dicetylphosphate and DODAC. Other candidates are sulfatides, 
gangliosides, dialkylphosphates etc. Liposomes can also be prepared from mixture of 
phospholipids and the mean packing parameter is evaluated as weighted average of 
packing parameters of all the components. 
Additional constituents, apart from lipids, can also be used in preparation of 
liposomes for various reasons. For example antioxidants, chelating agents or cholesterol 
(acts as fluidity buffer) are included to enhance stability of liposomes. Moreover, 
optimization of temperature, pH and ionic strength of the medium are also important to 
produce more stable liposomes. Similarly, addition of cryoprotectants allows storage of 
liposomes in frozen and lyophilized form, while coating with inert hydrophilic polymers 
led to increase in stability. To avoid aggregation of liposomes charged lipids could be 
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incorporated. For prolonged presence of these in blood circulation, polyethylene glycol 
coated 'stealth' liposomes are used. Fusogenic liposomes are constituted by including 
glycerol, polyvinyl alcohol or reconstituted viral-membrane (virosomes). Actually, 
liposomes can be custom designed for almost any need by varying lipid content, 
additional components, size, surface charge and method of preparation. 
2.2 Preparation 
Several strategies are available for the preparation of various types of liposomes 
and entrapment of various substances therein. All the procedures include the steps of lipid 
film hydration, formation of the lipid bilayer followed by removal of un-entrapped 
material. The most common method employed is sonication either by a probe sonicator or 
a bath type sonicator (Huang, 1969), others being high-pressure exclusion, rapid injection 
of an ethanolic solution of a lipid into an aqueous solution (Batzri and Kom, 1973) or by 
iransgently increasing the pH of aqueous phospholipid dispersion (Hauser and Gains, 
1982). Removal of detergents by dialysis, solvent infusion and reverse phase evaporation 
(Buboltz and Feigenson, 1999) results in the formation of multi-lamellar vesicles 
(ML Vs). The simplest procedure, however, involves hand shaking or stirring of aqueous 
phospholipid dispersion. Following dehydration/ rehydration method, the entrapment 
efficiency of liposomes can be increased to 40% of the compound to be entrapped which 
is fairly higher than 2-10% for MLVs prepared by hand shaking method. Since the size of 
liposome is an important factor in its stability and tissue distribution in vivo, exclusion 
through polycarbonate membranes is routinely used to obtain a more uniform size 
distribution in the liposome preparation. Homogenization of MLVs results in the 
formation of unilamellar vesicles. It involves some or the other form of energy to be 
dissipated into the system of lipids and aqueous solvent for preparing liposomes. 
2.3 Nomenclature and Classification 
Initially, liposomes were classified on the basis of the name of the contributors 
who were directly involved in their development, e.g.- Banghamosomes for sonicated 
MLVs and Huangosomes for ULVs prepared by dispersion of the MLVs. More recently 
used nomenclature is based on composition, structure or method used in the preparation 
of liposomes. 
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2.3.1 Nomenclature based on Structure 
The most widely accepted terminology is based on size and number of lamellae 
present in the liposomes. Thus liposomes with more than one bilayer are multilamellar 
(MLV) and with single layer are unilamellar (ULV). The ULVs can be further classified 
on the basis of out/in ratio i.e. ratio of number of lipid molecules present in outer vs irmer 
monolayer of the liposomes. 
Type Specifications 
MLVs Multilamellar large vesicles 
MVVs Multivesicular vesicles 
OLVs Oligolamellar vesicles 
Diameter 
>0.5 |im 
0.1-20 ^m 
0.1-1.0 |am 
Out/in ratio 
ULVs Unilamellar vesicles 
SUVs Small unilamellar vesicles 
MUVs Medium unilamellar vesicles 
LUVs Large unilamellar vesicles 
GUVs Giant unilamellar vesicles 
20-40 nm 2 to 2.4 
40-80 nm 1.2 to 1.5 
>80nm 1 to 1.2 
> 1 |im 1 
2.3.2 Nomenclature based on method of preparation 
The nomenclature does not provide information regarding properties of liposomes. 
Methods of preparation of liposomes used for naming liposomes, such as: 
Type Method 
REV 
MLV-RLV 
Single or oligolamellar vesicles made by 
reverse phase evaporation method 
Multilamellar vesicles made by 
reverse phase evaporation method 
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SPLVs 
FAT MLVs 
VET 
DRVs 
Stable plurilamellar vesicles 
Frozen and thawed MLV 
Vesicles prepared by extrusion technique 
Dehydration-rehydration made vesicles/dried 
reconstituted vesicles 
2.3.3 Nomenclature based on composition 
Various constituents included in preparation of liposomes as well as other characteristic 
features can also be used as criteria for their nomenclature: 
Type Characteristic 
Conventional liposomes (CL) Neutral or negatively charged 
phospholipids with/without Cholesterol 
Fusogenic liposomes 
pH sensitive liposomes 
Fusogenic lipids/viral components 
Phosphatidyl-ethanolamine with 
cholesterol hemi-succinate or PE with 
oleic acid liposomes or Cationic lipids 
with DOPE 
Stealth liposomes Choi and 5-10% of PEG- DSPE or GMl 
Archaeosomes Made of lipid from Archaebacteria 
Escheriosomes Composed of £. coli membrane lipid 
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Proteoliposomes Liposomes with encapsulated/surface 
attached proteins 
Immunoliposomes Liposomes with covalently attached 
mono/polyclonal antibodies 
Genosomes DNA-Hposomes/Hpid complexes 
Lipofectin Lipid-DNA complex 
2.4 Fate of liposomes inside host body 
Liposomes administered into host may disintegrate in bloodstream or may 
wander in the systemic circulation and picked up predominantly by macrophages. 
Actually, endothelial lining of healthy blood vessels forms an efficient barrier to the 
liposomal escape from circulation. However at the site of inflammation, endothelium is 
more permeable and allows extravasations of small liposomes. This leads to the rapid 
clearance of liposomes from the blood circulation and their capture by the organs of 
reticulo-endothelial system (Poste, 1983; Allen et al, 1988), corresponding to the tissue 
distribution pattern of some pathogenic microorganisms responsible for intracellular 
infections. Passive site-specific drug targeting with liposomes, as it is called, may 
facilitate lowering of the drug dosage relative to the amount of the free drug used, thereby 
reducing the potential toxic side effects exerted by higher doses of the drugs. However, 
this clearance is too fast to benefit other tissues from it. PEG-coated stealth liposomes 
have long half-life in blood circulation and may act as a reservoir for sustained release of 
the therapeutic agents for longer duration. Antibodies or other homing devices covalently 
attached to the surface make the liposome uptake tissue and cell specific. 
The applications of liposomes in drug delivery are based on physicochemical and 
colloidal characterization such as composition, size and loading efficiency and the 
stability of the carrier, as well as their biological interactions with the cells. The major 
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interactions between the liposomes and cells are as follows. Lipid exchange is a long-
range interaction that involves the exchange of liposomal lipids for the lipids of various 
cell membranes. It depends on the mechanical stability of the bilayer and can be reduced 
by alloying the membrane with the cholesterol (which gives rise to greatly improved 
mechanical properties, such as increased stretching elastic modulus, resulting in stronger 
membranes and reduced permeability). The second major interaction is adsorption onto 
cells, which occurs when the attractive forces (electrostatic, electrodynamic, Vander 
waals, hydrophobic interaction and hydrogen bonding etc.) exceed repulsive forces 
(electrostatic, steric, hydration, ondulation, protrusion etc.). Adsorption onto phagocytic 
cells is normally followed by endocytosis or rarely, by fusion. The fusogenic liposomes 
mimic the way by which several viruses (HIV, Sendai virus) bind and merge with cell 
membranes at neutral pH and subsequently release their content into the cytoplasm. 
2.5 Liposomes - Applications 
Liposomes are being used for a range of therapeutic and pharmaceutical 
applications. Some of them are listed as below: 
• As drug/protein delivery vehicles 
• In anti-bacterial, anti-fungal and anti-viral therapy 
• As biological response modifiers 
• In tumor therapy 
• In Immunology 
• In enzyme replacement therapy 
• In gene delivery 
• In environmental cleansing 
• In cosmetics and dermatology 
• In enzyme immobilization and bioreactor technology 
• In Recombinant DNA technology 
• As artificial blood surrogates 
• As radiopharmaceutical and radiodiagnostic carriers. 
However, the most important and wider field, which has been revolutionized by 
liposomes, is drug-delivery and targeting. 
2.5.1 Liposomes as drug carriers 
Advantages of using liposomes: 
Resemblance to bio-membranes: The liposomes are biodegradable, inert, non-toxic 
delivery systems usually composed of lipids isolated from plasma membranes of the 
living cells. Various types of liposomes can be prepared by varying size, morphology, 
and composition. 
Solubilisation: Liposomes may solubilise recalcitrant drugs/compounds. 
Versatile carriers: Axnphipathic nature of liposomes facilitates the incorporation of both 
hydrophilic as well as hydrophobic drugs. The drugs of intermediate solubility can be 
associated with liposome interior by manipulation of liposomal internal pH (Mayer et al, 
1986) or by addition of counter ions to form molecular complexes of the drug within the 
liposomes (Haran et al, 1993). 
Flexibility: Liposomes can be formulated as a suspension, as an aerosol or in a semisolid 
form such as gel or cream or dry powder, for their topical or potential in vivo 
administration. 
Targeting potential: Property of liposomes to be taken up by the macrophages and RES 
can be utilized for passive delivery of drugs to the liver and spleen. Surface engineered 
versions of liposomes have increased circulation time and deliver drugs to specific tissues 
by circumventing passive uptake by RES-predominant organs. 
Duration of Action: Liposomes can help in maintaining relatively constant and sustained 
blood plasma levels of drugs and give rise to long lasting effects. 
Internalization: The endocytosis/phagocytosis of liposomes opens up opportunities for 
use in targeting of drugs, genes, enzymes etc. to the desired population of cells. 
Amplification: Liposomes can be used as adjuvants in vaccine formulations. 
Protection: Liposomes-encapsulated drugs are inaccessible to metabolising enzymes. 
Conversely, body components like RBC and heart, are not exposed directly to toxic 
effects of drugs. 
Altered Pharmacokinetics: Relative to the same drug in free form, tliere are significant 
changes in absorption, bio-distribution and clearance of liposomes-associated drugs, 
resulting in dramatic effects on both the efficacy and toxicity of the entrapped compound. 
2.5.2 Limitations of using liposomes: 
• Liposomes tend to aggregate or lose entrapped drug during storage. 
• There is no suitable method of their sterilization by irradiation or by heat. 
• The macrophages of RES can take up liposomes before reaching their target 
organs. 
• High-density lipoproteins tend to interact with liposomes, in vivo, leading to 
leakage of encapsulated species. 
• Liposome preparation techniques are difficult to scale up using traditional 
methods. 
2.5.3 Liposomes and control of multi drug resistance 
Carefiil selection of proper antibiotics allows successful inhibition of 
multiplication as well as complete eradication of the pathogens from the host. Each kind 
of organism may be inhibited by specific antibiotic and also by specific drug dose. 
Therefore attributes made for selection of correct antibiotics are fundamental to the 
success of any treatment. When drug entrapped in liposomes is administered, liposomes 
act as a carrier transporting and directing antibiotics to the infected tissues where the drug 
attains fairly high concentration needed to kill the pathogens. Besides increasing the 
efficacy of the drug, liposome mediated delivery regresses chances for the development 
of resistance as the drug concentration at site of infection maintained throughout the 
treatment period. The targeted delivery also minimizes exposure of normal cells to the 
drug and thereby chances of toxic manifestation are minimal. In addition, this also 
facilitates the diffusion of the drug preferably into the infected locus and persistently 
maintains the effectiveness for a long time. 
Multi-drug resistance in cancerous cells is often associated with the over 
expression of drug efflux pumps, known as P-glycoprotein pump (PGP) (Kartner et al, 
1985) and multi-drug resistance associated pumps (MRP), which expel the drug 
32 
molecules outside the cells resulting in less accumulation inside the cells. Various 
delivery systems including liposomes have been used in chemotherapy of a number of 
refractory cancers both in animals and clinical models (Endicott and Ling, 1989). Several 
mechanisms proposed, through which liposomes control multi-drug resistance in tumors 
are: 
• Negatively charged phospholipids (phosphatidylserine or cardiolipin) used in the 
liposomal formulations may directly regulate the expression PGP and MRP. 
• After endocytosis of drug-loaded liposomes, the lysosomal localization of the 
drug protects it from outflow by PGP by avoiding immediate contact with the transporter 
that is present at plasma membrane. 
• Liposomes may provide sustained and high levels of drug to cells over long 
period of time to reduce the chances of cells to be converted into resistant ones. 
• Liposomal drug delivery may help to overcome a broader range of drug resistance 
due to favorable pharmacokinetics. 
Interestingly, the combination of liposome-encapsulated drug with some other 
chemotherapeutic agents or immunomodulators makes it more effective in combating the 
problem of resistance. This strategy opens new vistas in treating the infectious diseases 
not responding to free forms of the drugs in lower doses or moderately higher doses. In 
normal course, C albicans isolates respond to the drug at 1 mg/Kg body weight dose of 
Amp B, however some of the strains were found to be less sensitive to the Amp B at 
lower doses and may need more than 5 mg/Kg dose for complete elimination. 
Incidentally, the higher doses of the Amp B are likely to impart untoward effects such as 
nephrotoxicity etc., and cannot be recommended for therapeutic purposes. 
2.5,4 Liposomes and antibacterial therapy 
Infections caused by intracellular pathogens, such as Brucella, Salmonella, 
Listeria, Legionella and Mycobacterium species, are difficult to treat with conventional 
anti-microbial chemotherapy because of the unfulfilled requirement that antibiotics 
should accumulate therapeutic levels at the intracellular site of the infection. When 
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antibiotics are incorporated in liposomes, these are readily delivered to the endosome of 
macrophages, thus targeting the drug to the site of infection. This approach provides a 
remarkable enhancement in the therapeutic index of antibiotics and reduction in toxic 
side effects. 
Liposomised streptomycin was shown to be more effective against 
Staphylococcus aureus and Escherichia coli (Fountain et al, 1985), as compared to the 
free drug. Gentamycin when encapsulated in positively charged liposomes could 
eliminate the Brucella melitensis (Hamandez-Caselles et al, 1989) and Klebsiella 
pneumoniae (Swenson et al, 1990) loads from the liver and spleen of the infected 
animals. The same liposomal preparation of gentamycin with changed lipid composition 
has also helped treat Salmonella dublin infections. Gentamycin encapsulated in pH-
sensitive liposomes was found to show increased efficacy against Salmonella 
typhimurium in model animal (Cordiero et al, 2000). The efficacy of liposomised 
preparation of other drugs such as amikacin, tobramycin and chloramphenicol against 
several gram-negative bacteria has also been reported (Stevenson et al, 1983). Chronic 
listerosis infection can be managed by an injection of liposomised ampicillin (Bakker-
Woundenberg et al., 1988) and has been 90 fold more potent than the free drug (Fattal et 
al, 1991). 
The association of tuberculosis with HIV infection has significantly exacerbated 
the situation in developed and developing countries. HIV infection is the highest risk 
factor identified so far for latent tuberculosis infection to progress to an active disease. 
Mycobacterial infections have long been notorious for being difficult to eradicate by 
conventional chemotherapy, can also be controlled using liposomal preparations. 
Liposomal encapsulation of Streptomycin (Vladirmisky et al, 1983), Isoniazid and 
Rifampicin (Orozco et al, 1990) can enhance efficacy of these drugs against 
tuberculosis. While liposomised rifampicin was able to control Mycobactrium avium 
infection in mice (Saito and Tomika, 1989). Different aminoglycoside classes of 
antimycobacterial drugs, amikacin and gentamycin, have also been shown to control 
mycobacterial infection more efficiently when encapsulated in liposomes (Bermudez el 
al, 1990; Kesavalu et al, 1990; Klemens et al, 1990). 
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2.5.5 Liposomes and antifungal therapy 
Systemic fungal infections occur at high frequency in the immuno-compromised 
patients such as those of cancer and AIDS patients as well as patients with organ 
transplantation (Landman and Saurina, 1998; Musial et al, 1988). Drug of choice for the 
most systemic mycoses is a polyene antibiotic Amphotericin-B, that interacts with 
ergosterol in fungal cell membranes thus creating transmembrane channels and 
permitting the escape of vital ions and metabolites. This drug although very promising, 
had limited use due to its systemic toxicity. Incorporation of Amp-B in liposomes 
successfully reduces its nephrotoxicity and thus improves the therapeutic index (Adler-
Moore and Proffitt, 2002). Numerous reports of liposomal Amp-B having enhanced 
efficacy against murine aspergillosis and candidiasis ( Van Etten et al, 1995; Otsubo et 
al, 1998), and against cryptococcosis, histoplasmosis, Fusarium infections etc. (Graybill 
et al, 1982; Adler-Moore et al, 1991; Garcia et al., 2000) are available. Table. 2 gives 
some of the important commercially available liposomal preparations of Amp-B. 
Other polyene antibiotics like nystatin and hamycin have also been successfully 
liposomised to improve their therapeutic index (Mehta et al, 1991). This led to the 
development of the liposomal preparation of Itraconazole in management of experimental 
cryptococcosis and pulmonary aspergillosis (Leconte et al 1992). 
2.5.6 Liposomes and antiprotozoal therapy 
The first successful use of the liposomal drug delivery system in infectious 
diseases was made in the treatment of leishmaniasis. This protozoan parasite, endemic in 
many tropical and subtropical areas, enters and colonizes macrophages and thus can be 
readily targeted by liposomes. In mice, liposome encapsulated antimonies have been 
shown to be about 700-1800 times more effective than the free drug in controlling 
leishmaniasis (New et al., 1978). Stilbamine encapsulated in mannose bearing liposomes 
has been used in treatment of the experimental leishmaniasis. Interestingly, some of the 
anti-fungal drugs like griseofulvin (New et al, 1981), Amp-B (Adler-Moore et al, 2002) 
and 5-fluorocytosine were demonstrated to exhibit an enhanced efficacy against 
leishmaniasis when used in the liposomal form. 
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It has been shown that when MSP-1 i.e Psurface protein -1 was uicorporated 
into a synthetic monophosphoryl Hpid A-Hposome formulation, mice of different 
haplotypes produced anti MSP-1 antibodies capable of inhibiting P. falciparum growth 
(Chang etal . 1994). 
The life cycle of the malarial parasite gets completed in different body parts of 
the host. Depending on its different life cycle stages, specific liposomal formulations of 
antimalarials have been shown to be of great promise in the treatment of malarial 
infection. Primaquine when entrapped in liposomes can cure murine malaria by using a 
single intravenous injection. The efficacy of primaquine containing liposomes can be 
increased several fold when such liposomes are made more specific for their target by 
grafting galactosyl glycolipid on their surface (Alving, 1982). Chloroquine, the most 
promising antimalarial, specific against intra erythrocytic stage of plasmodial life cycle, 
can be made very effective not only against drug sensitive but also drug resistant strains 
of P. berghei (Owais et al, 1995), by encapsulation in liposomes bearing antibodies 
directed against surface antigens of erythrocytes. 
2.5.7 Liposomes and antiviral therapy 
Liposome encapsulated macrophage stimulators, viz lymphokine, 
muramyldipeptide and its aminobuturyl analogue, were employed against Herpes simplex 
virus type-2 (HSV-2) infection (Koff e^  al., 1983;. Koff e/ al, 1984). Murine Rift Valley 
fever virus, rhinovirus and murine hepatitis virus could be controlled effectively by using 
liposomal preparations of ribavarin, enviroxime and y-interferon (Szoka, 1990). 
Liposomal formulation of phosphonoformate, was shown to have an improved 
immunomodulation against Rausher Murine Leukemia retroviral infection (Szoka, 1990). 
Intracellular delivery of novel drugs against HIV-1, including antisense 
oligodeoxynucleotides, ribozymes and therapeutic genes, may be achieved by 
encapsulation in or association with certain types of liposomes (Duzgunes et. al, 1999). 
The authors showed that EC50 of the reverse transcriptase inhibitor 9-(2-
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phosphonylmethoxyethyl) adenine (PMEA) was reduced by an order of magnitude when 
delivered to HIV-1 infected macrophages in pH sensitive liposome with the drug in 
liposomised form as effective as the free drug. 
CD4 receptors present on T cells are specifically recognized by glycoprotein 
'gpI20' present on the HIV coat. CD4 inserted in the liposomal bilayer effectively 
cleared both free HIV and 'gp 120' bound to HIV infected cells (Nicolau et al, 1990). 
Liposome encapsulated azidothymidine has been shovm to reduce the hematopoietic 
toxicity and enhance the activity of the drug against murine AIDS (Phillips and Tsoukas, 
1992). 
2.6 Liposomes and Immunology 
Besides its potential application in chemotherapy and gene therapy, liposome 
technology has established itself in the area of immunology as well. The major areas of 
interest from immunological point of view are: 
• Liposomes as adjuvants 
• Liposomal vaccines 
• Liposomes as carriers of immunomodulators 
• Liposomes as tools in immunodiagnostics (discussed in 'Liposomes & 
diagnostics' section) 
2.6.1 Liposomes as adjuvants 
Adjuvants are substance injected together with antigens to enhance their 
immunogenicity. Owing to toxicity of all the known adjuvants, only one (alum) has 
hitherto been licensed for use in humans in spite of the fact that it is far from ideal. 
On the contrary, liposomes may offer an alternative, versatile and imiversal adjuvant 
system with high safety profiles. Liposomal immunoadjuvants passively accumulate 
within regional lymph nodes and act as antigen depot by slowly releasing encapsulated 
antigenic components. Table. 3 provides list of antigens with which liposomes have been 
used. Liposomes have been firmly established as immunoadjuvants by potentiating both 
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antigen specific humoral (antibody production) (Alving et al, 1995) as well as cell-
mediated (cj^otoxic T lymphocytes) (Owais and Gupta, 2000) immunity. 
Some other advantages of using liposomes for immunopotentiation are as 
follows: 
• A non-immunogenic substance may be transformed to an immunogenic one. 
• Hydrophobic antigens may be reconstituted. 
• May incorporate multiple antigens and other adjuvants to provide strong immune 
response. 
• Toxicity of the antigens can be reduced or may be eliminated by inclusion into the 
liposomes. 
• Modulation of the immune system. 
• Liposomal vaccines produce higher titers of functional antibodies as well as 
prolonged duration of these antibodies. 
2.6.2 Liposomal Vaccines 
Liposomal vaccines can be developed by incorporating microbes, soluble antigens, 
cytokines or deoxyribonucleic acid in liposomes. Alternatively, antigens can be 
covalently coupled to liposomal membrane for increasing their immunogenicity (Wassef 
et al., 1994). Also for enhanced immunopotentiation, some other agents such as muramyl 
dipeptide (MDP), lipopolysachharide, lipid A and tuftsin can also be incorporated into 
liposomes (Schroit and Fidler, 1986; Singhal et al, 1984; Bennett-Guerrero et al, 2000; 
Richdixds et al, 1998). 
Some of the commercially available liposomal vaccines are enlisted in Table. 4. 
Most of the liposomal vaccines investigated to date are based either on novasome or IRIV 
(immunopotentiating reconstituted influenza virosome). Vaccines based on novasomes 
(non-phospholipid, biodegradable, pausilameilar vesicles formed from single chain 
amphiphiles, with or without other lipids) have been licensed for the immunization of the 
fowl against Newcastle disease virus and avian retrovirus (IGl, Vineland Laboratories, 
Vineland, NJ, USA) (Gregoriadis, 1995). 
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IRIVs are spherical, unilamellar vesicles with a mean diameter of-150 nm (Gluck 
et al, 1992). IRIVs are prepared by detergent removal of influenza surface glycoproteins 
and a mixture of natural and synthetic phospholipids containing 70% egg 
phosphatidylcholine, 20% synthetic PE and 10% envelope phospholipids originating 
from HlNl influenza virus. Thus IRIV combines several components that are known to 
contribute to immunostimulation and at the same time are non-toxic and bioacceptable. 
The first liposome based vaccine (against hepatitis A) for human use is IRIV vaccine 
produced by Swiss serum and vaccine institute, Berne, Switzerland known as "Epaxal-
Bema Vaccine" (Gluck, 1995). 
CD4^ T helper and CD8* T cytotoxic phenotype may be influenced by cytokine 
milieu, the differential expression of costimulatory molecules, antigen dose, differences 
in affinity at the TCR-peptide-MHC interface and adjuvants (Agrewala et al, 1996; 
Agrewala et al, 1998; Braciale et al, 1987; Liebana et al, 1999 ). In spite of activating 
the immune response of the host against exogenous eintigenic substances, even the 
liposomised form of the antigen usually results in activation of CD4"^  T cells, which helps 
in elicitation of antigen specific humoral immune response with enhanced production of 
antibodies. The induction of cell mediated immunity (CMI) to antigen is dependent on 
the activation of CD4"', MHC class II (T-helper cells) and CDS'", MHC class I (cytotoxic 
T cells) restricted T cells (Braciale et al, 1987; Unanue and Allen, 1987). T-helper cells 
(Th) facilitate cytotoxic T cell (CTL) and B cell responses, and help in the production of 
class switching and memory responses. Cytotoxic T cells represent the other effector arm 
of the cell-mediated immune response. T lymphocytes are of strategic importance in 
killing of the cells infected with intracellular pathogens and also towards surveillance 
mechanisms against cancer cells. The CD8"^  T cell phenotype can considerably influence 
the outcome of infection by intracellular pathogens. The role of cytotoxic T cells has 
been established and foimd to be crucial for protecting the host against diseases caused by 
intracellular microbes and viruses (Unanue and Allen, 1987; Nickell et al, 1993; Muller 
et al, 1991; Flyrm, et al, 1992; Deres et al, 1989). Since, both cytotoxic as well as T 
helper cells are crucial for protecting the host against intracellular pathogens, to mount an 
effective immunity against such infections, it is important to develop vaccines that 
generate strong 004"^ and CDS"^  T cells responses (Flynn, et al, 1992; Tarleton et al, 
1992; Bottomly, 1988). 
The lipid composition of plasma membrane of various organisms plays crucial 
role in their different physiological activities, e.g. fertilization, phagocytosis, exocytosis 
and cell division especially in perspective of membrane-membrane fusion (Voet et al, 
1999; White, 1992). Lower organisms, such as bacteria and yeast, have many fusogenic 
(anionic) phospholipids in their membranes, presumably to cope with the high 
multiplication rate (Krishnan et al, 2000; Conlan et al, 2001; Rattray. 1988; Owais and 
Gupta, 2000). Such lipids seem to facilitate the fusion of the two opposite sites of inner 
leaflets under physiological conditions. It was demonstrated that the E. coli lipid 
liposomes (escheriosomes) very effectively fused with the membrane of the macrophages 
leading to the delivery of entrapped solutes or antigens to their cytosol. Moreover, the 
studies have revealed that antigen entrapped in these liposomes could generate strong 
OVA-specific, CD4"^  T-helper as well as CD8^ cytotoxic T cells. The T-helper response 
was chiefly of Th-2 type, as evident from the secretion of IL-4 and IgGl-isotype (Stevens 
et al, 1988; Shaji et al, 1998). On the contrary, the same antigen after encapsulation in 
egg PC liposomes induced humoral immune response mainly (Owais & Gupta, 2000). 
Protective immunity against intracellular bacteria (tuberculosis, leprosy), fungi 
(cryptococcosis, candidiasis), protozoans (leishmaniasis, malaria), viruses and cancer 
requires active involvement of the pathogen specific CD%^ T lymphocytes (Malik et al, 
1993; Sasiain et al, 1998; Liebana et al, 1999; Nickell et al, 1993; Muller et al, 1991; 
Deres et al, 1989). Ironically, prevalent iimnunization protocols result in the development 
of humoral immune response mainly; on the contrary generation of cytotoxic T cells 
always remains a major uphill task (Audibert and Lise, 1993; Leclerc and Ronco, 1998). 
Moreover, some of the presently available antigen delivery systems viz. Virosomes, pH 
sensitive liposomes or fusogenic protein bearing liposomes, which are claimed to induce 
strong immunogenic responses against entrapped antigen, carmot be recommended 
because of cost factor, toxicity as well as structural components {of. carbohydrate) 
induced immunological complications (Mandal and Lee, 2002; PoIt-Frank et al, 1999; 
Lee- ki et al, 2002; Kunisawa et al, 2001; Babai et al, 2002; Harding et al, 1991). 
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Liposomised antigens are avidly taken up by the antigen presenting cells, and 
lead to the production of IL-4 mainly (Agrewala et al, 1996). Thus in spite of the 
adjuvant effect of liposomes in terms of increased humoral immunity, they miserably fail 
to activate the cell-mediated immunity. To meet demand of the ordeal, escheriosomes and 
yeast lipid liposomes were evaluated for their ability to breach cell membrane barrier and 
deliver entrapped solutes in the cytosol of the of the target cells including macrophages. 
The potential of escheriosomes to activate the cell mediated arm of the immune response 
enables them as an ideal vaccine adjuvant against diseases caused by intracellular 
pathogens. 
2.6.3 Liposomes in immunomodulation 
Interestingly, incorporation of cytokines or other immunomodulators have been 
found to activate various immune components of the host. Activation of the immune 
system for the management of certain types of tumors like micrometastases and 
osteosarcoma is a well-accepted treatment modality. The main purpose is to activate 
macrophages and render them tumouricidal, with the specific ability to recognize and 
destroy neoplastic cells both in vitro and in vivo, while leaving normal cells unharmed by 
a non-imniunological reaction mechanism that requires cell-to-cell contact (Tucker et al, 
1981). 
2.7 Liposomes and antitumor therapy 
Most of the medical applications of liposomes that have reached preclinical and clinical 
stages belong to cancer ailments mainly. It has been demonstrated that small-sized and 
long circulating liposomes can be passively targeted to different tumors because of 
extended circulation and extravasation (owing to their small size, 50-150 nm) in tissues 
with enhanced vascular permeability (Gregoriadis et al, 1971; Gabijon and 
Papahadjopoulos, 1992). Long-circulating pegylated liposomes were able to deliver 
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between 5 to 11 times more doxorubicin to the Kaposi's sarcoma lesions than to normal 
skin, leading to overall response rates as high as 80% (Northfelt et al, 1996), and also 
decreased uptake of drug by sensitive tissues such as the heart (Uziely et al, 1995). 
Preclinical experiments indicate that stealth liposomal delivery of anthracyclines is 
effective in decreasing the cardio toxic effect, enhancing antitumor activity and 
improving the overall therapeutic index (Alberto Gabizon, 2000). 
Targeting strategies using liposomes can be designed in three different ways: 
<• Natural targeting (lysosomotropism) of conventional liposomes (passive 
vectorization). 
<• Use of long -c i rcula tory (stealth) l iposomes. 
<• Use of ligand mediated targeting (active targeting). 
(a) The use of anti-receptor antibodies or antibodies developed against specific 
surface antigens on the tumour vascular endothelium; 
(b) The use of angiogenic peptides and adhesion molecules as ligands against 
receptors expressed on tumour vascular endothelium. 
<• Use of stealth liposomes and ligand mediated targeting in combination. 
Sterically stabilized (stealth) liposomes (SSL) 
The site specific drug targeting requires proper and smartely designed delivery systems 
that avoid scavenging through receptor mediated uptake by mononuclear phagocytic cells 
of RES-rich organs. Moreover, several targeting strategies require the system to be placed 
either into the tumour cells or their extravasation into non-RES cellular lineage. As a 
matter of fact, recently described approaches to avoid RES-uptake of the drug carrier 
composites, lead to the concept of ligand- appended system, which resist opsonization 
and serum protein binding to their surface. Sterically stabilized liposomes thus avoid their 
recognition from RES uptake and this "stealthing" effect makes them long circulatiry in 
nature. 
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Rational and Concept of using Stealth Liposomes in Tumour Targeting 
Major aims and benefits of sterically stabilized liposomes (SSL) or stealth liposomes are 
as following: 
*l* Making liposomal systems more stable in bioenvironmental conditions. 
<• Making them long circulatory (i.e., less recognizable to serum proteins specially 
opsonins and hence less recognizable to phagocytic cells of RES) 
<* Making the targeted along with long circulatory behaviour by anchoring site specific 
ligands. 
•> Making them more sensitive towards external stimuli and signals like pH, substrates 
and temperatures. 
*l* Making them more suitable for tumour targeting 
The potential of stealth liposome for tumour targeting can be realized by following 
attributes: 
1. Long circulatory liposomes with encapsulated anticancer drugs can reach sites other than 
RES (if tumour belongs to an extravascular site), either by extravasation through leaky 
blood vessels in tumours or directed through surface attached ligands (mostly antibodies). 
2. They can serve as the sustained release micro reservoirs for the anticancer drugs. This 
can be either long-circulatory systemic application, local injection to body cavities, such 
as intraperitoneal, or intramuscular or subcutaneous drug depot with customized 
permeability or leakage chracterstics. 
3. They may be used in direct applications, such as delivery of free redical oxygen to 
enhance radiotherapy or other photo- and radiotherapeutic substances. 
Keping into consideration amplified expression of folate receptor in cancer cells, 
it has been shown that folate-derived liposomes have effectively delivered entrapped 
agents into tumor cells via receptor-mediated endocytosis (Pan el al, 2002). Folate has 
been coupled to distearoyl phosphatidyl ethanolamine (DSPE) using a PEG 2000 linker 
(Folate-PEG 2000-DSPE) to deliver liposome encapsulated doxoerubicin has been 
reported over that observed for non targeted vesicles (Lee an Low, 1994a, 1994b). More 
recently, reports appeared on Arginine-Glycine-Aspartic acid (RGD) peptide driven 
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targeting of liposomes to endothelial cells to block angiogenesis in tumours. RGD 
tripsptide, being a fragment of fibronectin, discourages melanoma cells from spreading 
(metastasis), presumably RGD molecules block the receptors that a wandering tumour 
cell need for binding to fibronectin and hence in the extracellular matrix of the tissue. 
Nishiya and Sloan, 1996 prepared DMPG/DMPC liposomes incorporating RGD-PE 
and demonstrated that RGD ligand could increase platelet uptake of liposomes by four to 
five-fold over unmodified vesicles . 
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Table. 1: Role of liposomes in various disciplines 
Cell biology and 
Physiology 
Biochemistry 
Biophysics 
Drug therapy and 
Enzyme therapy 
Immunology 
Excretion, cell function, trafficking and signaling, studies 
pertaining to function of genes 
Function of membrane proteins, catalysis, energy conversions etc. 
•s of cell membranes, membrane channels, studies pertaining to 
ismembrane proteins etc. 
Acts as a depot for sustained release of various anti-cancer and 
antifungal drugs as well as enzymes of therapeutic significance. 
s a vaccine carrier and adjuvants for increased humoral and 
CTL response. 
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Table. 2: Liposome-based Antibiotics/Antineoplastics 
System 
Liposomes 
AmBisome 
Amphocil 
ABELECT 
AMPHOLTEC 
Mikasome 
Doxil 
Daunoxome 
EVACET'^ 
VincaXome 
Liposomes 
Drug 
Nystatin 
Amphotericin B 
Amphotericin B 
Amphotericin B 
Amphotericin B 
Amikacin 
Doxorubicin 
Daunorubicin 
Doxorubicin 
Vincristine 
Anamycin 
Target Disease 
Systemic fungal infections 
Systemic fungal infections 
Systemic fungal infections 
Systemic fungal infections 
Systemic fungal infections 
Bacterial infections 
Metastatic cancers 
Metastatic cancers 
Metastatic cancers 
Solid tumors 
Kaposi's sarcoma 
Company 
AroneX, USA 
NeXstar, USA 
SEQUUS, USA 
Liposome Co. USA 
Sequus, USA 
NeXstar, USA 
SEQUUS, USA 
NeXstar, USA 
Liposome Co, USA 
NeXstar, USA 
AroneX, USA 
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Table. 3: List of Antigens with which liposomes have been used as 
immunoadjuvants 
Antigen Liposome / Effect 
Influenza subunit antigen 
Bacterial polysaccharide 
Rabies glycoprotein 
Polio virus peptides 
Cholera toxin 
Toxoid of B. pertussis 
Tetanus toxoid 
Diptheria toxoid 
Herpes simplex virus 
Hepatitis B virus surface antigen 
Intranasal, protects animals from virus 
Superior immunoadjuvants 
Ag specific IL-2 enhancement 
Enhanced Ab level 
Superior immunoadjuvants 
Very effective vaccine 
Mannose-mediated liposomal targeting, 
increased antibody titre 
Higher Ab response 
MLV with lipid A, Enhanced Ab level 
Humoral and cellular immunity 
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Table. 4: Liposome based vaccines either approved or licensed for use in 
human 
System 
Novasomes 
Novasomes 
Novasomes 
Novasomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
IRIV 
liposomes 
Components 
Killed new castle disease 
virus 
Killed avian retrovirus 
E.coli0157:H7 (killed) 
Shigella flexneri 
Haemagglutinins/neuraminid 
ase from influenza strains 
Inactivated hepatitis A 
virions 
Genetically engineered 
Hepatitis A and B 
components (HAV) 
Diptheria and tetanus toxoids 
Diptheria and tetanus toxoids 
+HAV virions 
Target Disease 
New castle disease 
Retroviral 
infection 
E.coli 0517 
infections 
S. flexneri 
infections 
Influenza 
Hepatitis A 
Hepatitis A and B 
Diptheria and 
tetanus 
Diptheria, tetanus, 
Hepatitis A and B 
Company 
IGI, Vineland 
Lab, NJ, USA 
IGI, Vineland 
Lab, NJ, USA 
Novavax, USA 
Novavax, USA 
Swiss serum 
and Vaccine 
Int., Switz. 
Swiss serum 
and Vaccine 
Int., Switz. 
Swiss serum 
and Vaccine 
Int., Switz 
Swiss serum 
and Vaccine 
Int., Switz 
Swiss serum 
and Vaccine 
Int., Switz 
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i^mm 
PAKT III 
MMUNOPOTENTlATIh]^ 
nOLE Of 
IMMUhJOMOVULATOnS 
Normally, the immune system of a healthy person confronts well with the 
invading pathogens leading to their successful elimination from the body. The 
establishment of the infection could be made possible in situations such as over exposure 
with the pathogens (in terms of their number as well exposure time), invasion with highly 
virulent strain or because of the suppressed immune status of the host. Initially, the 
invasion leads to local or general colonization of the infection, the escaping microbes 
once find conducive conditions, start multiplying and eventually get disseminated to 
various parts of the body. Meanwhile immxme system also gets activated and applies all 
possible measures leading to elimination of the pathogens. The war keeps on going unless 
one overpowers other. 
Clinical management should, therefore, involve the restoration of the balanced 
immune status as the first measure to control of various infectious diseases. Some 
bioactive substances may offer a strategy to manipulate or alter the state of the immune 
system in favor of host (Hancock and Chappie, 1999). These substances better referred as 
immunomodulators are able to influence all vital physiological processes and can play an 
important role to normalize homeostasis. Restoration of the balanced immune system can 
be achieved by using the immunomodulators that can support other chemotherapeutic 
agents for their ability to eliminate infections. Moreover, these immunostimulatory agents 
or immune adjuvants are not only able to restore the normal response in 
immunocompromised conditions but can boost the immune status of the subjects 
susceptible to infective invasions. 
Advances, made in recent years regarding the understanding of molecular or 
cellular basis of immime responses, suggest a much vital role of immunomodulators in 
fighting various infections. Till date a number of immunomodulators, including small 
peptides, have been recognized modulate the natural immune response either specifically 
or non-specifically. These immunomodulators can provide clinical help not only in 
diseases such as tuberculosis, leishmania and fungal infections, where macrophages, the 
prime immune cells are impaired by parasites, however also in common viral infections 
and in immunologically related neural disorders. Tuftsin, an established 
immunomodulator, for example brings morphological changes in the neurons of visual 
and sensorimotor cortices and also affects their locomotory activity (Chebotareva, 1990). 
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The immunoregulatory therapy is a preventive therapy and if used in combination 
with chemotherapy, can help in treatment of infectious diseases as well. It would be even 
more valuable in patients who are in immunocompromised state due, either to infection 
itself or surgical trauma, irradiation, cancer chemotherapy and severe bums etc (Turanek 
et al, 1997; Talmadge et al, 1984). In combination therapy, it is likely that the 
antibiotics/antiviral agents would reduce the magnitude of the infection, while the 
immunomodulatory agents would stimulate the natural immune response of the host for 
better fight. This eventually would help in complete elimination of the infection and may 
also reduce the chances of recurrence of infection. Since phagocytes are important in 
clearing the infectious agents, immunomodulators capable of stimulating their activity 
would be more helpful in such cases. 
Moreover, keeping in view the fact that non-specific defense mechanisms are 
important in controlling tumor growth and reducing the probability of metastasis, the 
immunoadjuvants that can enhance the cytotoxic activity of natural killer cells and 
macrophages could help in cancer therapeutics (Abe et al., 1984). In spite of the fact that 
they are not so effective as first line of therapy, however, could prove very useful as 
supplement to cytoreductive therapies like surgical resection, irradiation etc (Turanek et 
al, 1997). For example, Thymostimulin and thymic extract are found to reduce the 
chemotherapy induced toxicity and prolongs the survival of the cancer patients 
(Maclihiarini er a/., 1989). 
Therapeutic use of such immunomodulators would be much precise and 
advantageous if their mode of action is understood well and is taken into account before 
using them in combination with particular vaccine/chemotherapeutic agent against a 
particular disease. 
TUFTSIN 
In 1970, Najjar and Nishioka demonstrated that Leukokinnin, a leukophilic 
fraction of immunoglobulin IgG, splits under the action of specific enzyme 
(Leukokininase) located in the outer membrane of neutrophils. The biological activity of 
leukokinin rests in a peptide tuftsin- so called because it was discovered at Tufts 
University (Najjar el al, 1970). Tuftsin is a 289-292 (Thr-Lys-Pro-Axg) sequence in the 
CH2 domain of the Fc fraction of the IgG molecule. 
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The tetra-peptide is released physiologically as a free peptide fragment after enzymatic 
cleavage (Najjar et al, 1987). Two enzymes are responsible for the production of tuftsin 
from leukokinin, tuftsin endocarboxypeptidase, a specific enzyme that cleaves the heavy 
chain at the Arg-Glu bond between residues 292-293, and the membrane enzyme 
leucikinase acts on the bound leucokinin-S to cleave it at the amino end of threonine 
between residues 288 and 289. Tuftsin is known to bind specifically to macrophages, 
monocytes and PMN leukocytes and possess a broad spectrum of activities related to the 
function of immune system primarily (Najjar et al, 1987; Fridkin et al, 1989). These 
include potentiation of various cell functions, such as phagocytosis, pinocytosis, motility, 
immunogenic response, fungicidal, bactericidal and tumoricidal activity (Fridkin et al, 
1989). The features of tuftsin coupled with its low toxicity make the tetra-peptide a 
promising candidate for immunotherapy (Nishioka et al, 1986; Khare et al, 1997). 
Tuftsin capacity to augment cellular activation is mediated by specific receptors that have 
been identified, characterized and isolated from rabbit granulocytes (Bump et al, 1986). 
Tuftsin and many of its analogs have been chemically synthesized and studied 
extensively for structure- function relationship (Nishioka et al, 1995; Gershonov et al, 
1996). 
The grafting of tuftsin on the liposomal surface would, therefore, enabled it not 
only in homing the liposomised-drug to the cells possessing receptors to recognize it, 
however also stimulate these key ceils of the immune system non-specifically against 
various infections (Singhal et al, 1984). Structure-function studies of tuftsin indicate that 
its binding and consequent MPS activation is dependent upon rather strict conservation of 
its molecular structure. Thus the modification of the peptide at its N-terminus or within 
the chain leads to a significant reduction or even loss of biological activity and also its 
ability to bind to PMN leukocytes is reduced (Fridkin et al, 1981). As tuftsin is a 
hydrophilic molecule, it would preferentially reside in the aqueous compartment of 
liposomes and would not have accessibility to its putative receptors present on the surface 
of various immune cells. Therefore, the tuftsin was grafted on liposomal surface by 
attaching a long hydrocarbon fatty acyl residue to the C-terminus through an Ethylene-
diamine spacer arm (Thr-Lys-Pro-Arg-NH-(CH2)2-NH-CO-Ci5H3i) (Singhal et al, 1984 ). 
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The incorporation of tuftsin at a percentage of >10 mol% tuftsin in the egg 
PC/cholesterol (7:3; mol/mol) liposomes was not possible as the resulting mixture could 
not be dispersed even by the long sonication (Singhal et al, 1984). On the other hand, the 
liposome containing lower mol% of tuftsin was only poorly bound to PMN leukocytes. 
Therefore, 7-8 mol% tuftsin in the liposomes is important for the optimal effect. The 
leakage rate of 6-Carboxy- fluorescin from egg PC/Cholesterol/tuftsin liposomes in 
which buffer of pH 7.4 at 37 °C was about 2-4%/hour. Incidentally, this leakage rate was 
dramatically enhanced upon incorporating another tuftsin derivative, Thr-Lys-Pro-Arg-
NH-CigH37 in the liposome bilayer (Singhal et al, 1984). This was probably due to 
binding of the dye with positively charged Arg residue in the analogue. Since this amino 
acid residue should be aligned just at the bilayer interface, the effect of its binding with 
the 6-CF on the liposomes permeability must have been mediated through perturbation of 
the egg PC head group packing in liposomes bilayer (Hauser et al, 1981). The 
binding/uptake of the egg PC/Chol/tuftsin liposomes to PMN leukocytes was saturable, 
time dependent and the cell bound liposomes are apparently taken up by the cells by 
receptor-mediated endocytosis without losing their structural integrity. This was ftjrther 
supported by the fact that endocytosis was inhibited by lowering the incubation 
temperature to 0° C (Singhal et al, 1984). The specificity of these liposomes was also 
examined v^th other blood cells i.e. erythrocytes, lymphocytes and foimd that no binding 
with erythrocytes was observed but there appeared some binding with lymphocytes 
which was presumably due to the presence of PMN leucocytes/monocytes as 
contamination in the lymphocyte preparation (Singhal et al, 1984). 
It has been demonstrated that tuftsin could enhance non-specific defense against 
infections by activating the macrophages (Singh et al, 1992). The biological activity of 
the peptide was due to the induction of the macrophage respiratory burst and activated 
macrophages exhibited enhanced levels of NADPH oxidase, O2, H2O2 and 
myeloperoxidase (MPO). Both super oxide and H2O2 damage proteins, nucleic acids and 
membranes sufficiently to kill the cell or even the whole organism. Moreover, for 
macrophages hypohalous acid produced by action of MPO on H2O2, has been identified 
as the major killer agent (Klebanoff e/ al, 1980). 
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3.1 Anti-tumor activity. 
Many workers have reported the anti-tumor activity of tuftsin against experimental 
tumor models (Nishioka et al, 1981; Nishioka et al, 1983). Florentin et al stated that 
tuftsin is able to potentiate various types of immune response when injected into mice, 
and can be used as a potent activator of macrophages in cancer therapy (Florentin et al, 
1978). This was also confirmed by the finding that tuftsin treated mouse peritoneal 
macrophages exert cytostatic activity for tumor cell proliferation (Bruley-Rosset et al, 
1981). Tuftsin was also reported to enhance the cytotoxic response of human monocytes 
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against K562 tumor cell line at the doses of 5 x 10' to 5 x 10" |a.g/ml. In contrast, the 
natural killing activity of lymphocytes against that particular cell line was not affected by 
tuftsin (Caroll et al, 1982). Tuftsin was also used for the treatment of cancer in humans 
with corresponding experiments in animals (Catane et al, 1983). Tuftsin at the doses 
ranging between 50 and 500|ig/kg of the body weight enhances the cytotoxic activity of 
mononuclear cells in mice and human, and, in mice, also shows antitumor activity. The 
effect of tuftsin was accompanied by leucocytosis induction (Catane et al, 1983). ft was 
also stated that tuftsin significantly increases survival rates among Rauscher virus 
leukemia infected mice and demonstrates antitumor activity against murine melanoma in 
vivo (Knyszynski et al, 1983; Noyes et al, 1981). 
3.2 Immunopotentiating effect 
The primary effect of tuftsin, after binding to receptors, consists of stimulation of 
macrophages and polymorphonuclear (PMN) cells. Specific binding sites of tuftsin are 
also localized on human monocytes. Tuftsin administered to the cell cultures stimulates 
the production of some cytokines. Intraperitoneal (i.p.) injection of tuftsin increases the 
production of TNF-a in serum and supematants of cultured splenic and peritoneal cells 
(Wleklik et al, 1987). Robey et al showed that tuftsin as well as its analogs, [Gly'j-
tuftsin, [Leu'*]-tuftsin, and [Gln'']-tuftsin (all being fragments of human C-reactive 
protein), induce monocytes to produce IL-1 (Robey et al, 1987). Recently, it was also 
found that treatment of mouse peritoneal macrophages with tuftsin or tuftsin-THF-Y2 
chimeras in the presence of antigen augments the IL-6 production (Granoth et al, 1997). 
In this way, tuftsin may perform its immunoregulatory functions and may influence 
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inflammatory processes by enhancing the IL-2 formation induced by IL-1. It was initially 
found that tuftsin stimulates phagocytosis after binding to PMNs. Subsequently 
phagocytosis stimulating activity of tuftsin in monocyte-macrophages was also 
demonstrated by some workers (Coleman, 1986). 
Tuftsin also potentiates antibody levels following the simultaneous injection 
along with a T cell-dependent antigen to mice with genetically controlled defect in 
affinity maturation, however did not affect antibody affinity in the same mice (Holland et 
al, 1990). Since peritonitis caused by Candida albicans is a major complication of 
continuous ambulatory peritoneal dialysis (CAPD), the activation by tuftsin of peritoneal 
macrophages may be considered a potential therapeutic option in that disease (Kain et al, 
1989). Kazanowska et al studied the influence of tuftsin on the fiinctions of granuloytes 
of children with acute lymphoblastic leukemia (Kazanowska et al, 1987). Tuftsin was 
found to increase the phagocytic activity of cultured Sertoli cells of rats as well in 
cultures of murine Kupffer cells (Filippini et al, 1989; Kubo etal, 1994). 
54 
3.3 Applications of tuftsin bearing liposomes in various 
infections 
3.3.1 Fungal Infections 
Opportunistic fungal infections remained to be a major problem in management 
of immuno-compromised patients. The presence of any fungal disease implies that host 
defense system has been compromised. Of late opportunistic fungal infections considerd 
to be major cause of morbidity in immuno-compromised human subjects. Patients with 
acute leukemia, especially following hospitalization and administration of antibiotics, are 
prone to various fungal infections and their early diagnosis in cancer patient still remains 
elusive (Horn et al, 1985). Chemotherapy with anti-fungal agents is a priory for both 
systemic as well as superficial fungal infections in humans. Various commonly used anti-
fungal chemotherapeutic agents include; Polyenes, Azoles, Allylamines, Morpholines, 
Flucytosin, Griseofulvin, Iodides, Hydroxy-stabamine and imidazole classes of drugs. 
The elimination of the fungi from the tissues of normal healthy persons is often 
accompanied with stimulation of cell-mediated immune response, which involves 
activation of mononuclear phagocytes by sensitising T cells. Treatment with anti fungal 
drugs in combination with tuftsin provoke macrophages/monocytes must find useful 
application in fungal chemotherapy (Owais et al, 1993). 
Amphotericin B, a polyene antibiotic, has been widely used in clinical practice to 
treat various fungal infections e.g. candidiasis, cryptococcosis, histoplasmosis and 
aspergillosis (Gallis et al, 1990; Lopez-Berestein et al, 1989). Besides, mild side effects 
associated with Amp B such as headache, chills, severe hemolytic anemia, nephrotoxicity 
is the most serious problem with amphotericin B therapy (Walsh et al, 1992). The 
toxicity of Amp B to cells originates from its binding to sterol present in the cellular 
membrane which involves disorganization of membranes by formation of specific pores 
composed of small aggregates of Amp B and sterol (Vanden et al, 1994). These defects 
cause depolarization of membrane and consequently an increase in the membrane 
permeability to protons and monovalent cations, which leads to cell death. 
With a view to further increase the efficacy of liposomised-Amp B, the 
drug was incorporated in tuftsin bearing liposomes and studied for its potential against A. 
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fumigatus infections in murine model (Owais et al, 1993).The results of tliese studies 
revealed that the percent survival of A. fumigatus infected mice increased (70-75%) by 
treating them with tuftsin bearing liposomal Amp B as compared to the animals that 
received treatment only with liposomal Amp B. The animals from the Tuft-lip-Amp B 
treated group were found free of infection whereas animals treated with liposomal Amp 
B still had some fungal load. These results strongly indicate that efficacy of Tuft-lip-Amp 
B increased remarkably against A. fumigatus infection due to tuftsin mediated activation 
of macrophages/monocytes, the key cells of host defense system. 
3.3.2 Malaria 
Malaria is still considered the most prevalent and devastating disease worldwide 
affecting about 300-500 million people and claims 1.5-2.7 million human lives. 
Furthermore, one-third of world human population dwells in the areas infested with the 
disease (Butler et al, 1997). Numerous efforts have been made for the development of the 
effective vaccines against malaria as effective vaccine may elicit a protective immune 
response in individuals of diverse genetic make up and could complement other strategies 
for prevention and control of this serious and most common public health problem in 
future. Although these strategies can provide crucial knowledge of nature of the 
protective host, immunological mechanisms and their respective target antigens but still 
there is no effective malaria vaccine, only chemotherapy remains the major practical 
option for managing all forms i.e. exo-erythrocytic and erythrocytic stages, of infection. 
Moreover, the situation is aggravating as the malarial parasites are rapidly developing 
resistance to the existing malarial drugs when given in classical pharmaceutical forms 
(Basco et al, 1998; Peters et al, 1998). 
It has been reported that pretreatment of mice with tuftsin, rendered them at least 
partially resistant to lethal P. berghei infection (Gupta et al, 1986). This effect of tuftsin 
gets further increased by incorporating tuftsin in the liposomes bilayer where both the 
mortality and parasitemea in the animals that received pretreatment with liposomal tuftsin 
were significantly reduced as compared to those pretreated with saline or control 
liposomes. The mean survival time of mice pretreated with 50 or 100 |ig doses of 
liposomal tuftsin were about 16 or 19 days, respectively, which were greater than that 
56 
observed with free tuftsin (Gupta et al, 1986). Since suppression of host immune 
response seems to be the reason in almost all Parasitic infections (Clayton, 1979), the 
immunomodulating agent such as tuftsin may help in bringing the immune status to 
normal, which in turn may fiirther enhance the efficacy of chemotherapy. 
3.3.3 Tuberculosis 
Tuberculosis is the single most disease that results in the largest number of deaths 
worldwide; nearly 3 million people are killed every year (Noordeen et al, 1988). The 
association of tuberculosis wdth HIV infection has further exacerbated the already 
complicated situation in developed and developing countries (Weiss, 1992). This 
infection also increases the risk to new tuberculosis infection that will progress to disease 
(Tuberculosis control and research strategies for the 1990s; WHO, 1992; Weiss, 1992). 
The most important factor in the treatment of tuberculosis is prolonged 
chemotherapy, for a minimum period of 6-12 months, which is often associated with 
serious and undesirable side effects e.g. hepatotoxicity (Girling, 1978; Raleigh, 1972). It 
is therefore desirable to develop an approach, which allows the use of lower drug doses 
with the use of delivery systems to the infected cells, thereby improving efficacy and 
potentially reducing toxicity. 
Liposomes can solve some of the above problems by serving as carriers of 
drugs for site specific or sustained delivery. Passive targeting of liposomes to MPS 
(Alving, 1986; Bakker-Woudenberg et al, 1994) could be utilized as M. tuberculosis 
resides and proliferates primarily with in the mononuclear phagocytes, which normally 
serve as the first line of defense against infections. Rifampicin, isoniazid, streptomycin, 
pyrazinamide, thioacetazone, ethambutol and p-amino salicylic acid are the front line 
drugs in the treatment of tuberculosis (Mitchison et al, 1988; Raleigh, 1972). A number 
of studies have demonstrated that the efficacy of these anti tubercular drugs can be 
increased by encapsulating or incorporating them in the liposome. Liposomes besides 
delivering the drug to the infected site could also act as drug reservoirs to provide slow 
and sustained release of the drug. This would not only reduce the cost of the treatment 
but may also minimize the duration of the treatment, two major drawbacks associated 
with the therapy of the tuberculosis. The use of liposomes as vehicles of rifampicin for 
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the treatment of tuberculosis has been demonstrated in mice (Agarwal et al, 1994). The 
drug acts on DNA dependent RNA polymerase in the bacterial cell to block the protein 
synthesis and kills the microorganisms. The anti-bacterial activity of rifampicin is high 
because it also kills the semidormant bacilli. The drug is thus comparatively safe, but its 
half-life in circulation is relatively short (3 hours) and most of the drug following oral 
administration is metabolized and excreted, leaving only a limited amount available for 
activity against mycobacterium. Thus daily dose of 600 mg of RFP is required for 
effective treatment, which often leads to serious side effects (Raleigh, 1972). 
The anti-tubercular activity of liposomised drug was considerably increased, as 
compared to free drug, because of the ability of liposomes to localize preferentially in 
macrophages/monocytes, leading a high intracellular drug concentration. This was further 
supported by the findings that intermittent treatment (twice weekly), with these 
preparations, was significantly more effective rather than the continuous treatment. The 
activity of the drug was further increased when the drug was loaded in tuftsin bearing 
liposomes. Rifampicin delivered in these liposomes was at least 2000 times more 
effective than the free drug in lowering the load of lung bacilli in infected animals 
(Agarwal et al, 1994). The dynamics of the distribution of RFP-liposomes in healthy and 
tuberculous mice showed that a greater liposome concentration in the liver, spleen and 
lungs of healthy mice was achieved, although the retention in tuberculous mice was 
longer. Besides tuberculosis RFP is also effective in leprosy and MAIS complex 
infections, thus widening the scope of RFP-loaded liposomes in treatment of a variety of 
mycobacterium infections. 
3.3.4 Leishmaniasis 
Leishmaniasis is caused by the haemoflagellate protozoan and represents four 
major clinical syndromes; visceral, cutaneous, mucocutaneous and diffuse cutaneuos 
leishmaniasis. It is estimated that worldwide more than 12 million people are infected and 
approximately 350 million at the risk. The most devastating clinical form, visceral 
leishmaniasis (kala azar) is caused by Z. donovani characterized by fever, 
hepatosplenomaegly, anemia and leukopenia. The major front line drugs for treatment of 
leishmaniasis are toxic. Several doses need to be given over a prolonged time period and 
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development of drug resistance is becoming a major problem. Since leishmaniasis affects 
the MPS cells, a number of studies exploit the liposomes as drug carriers for the 
treatment of leishamaniasis (Alving, 1986; Coukell and Brogden, 1998). 
The efficacy of several liposomal formulations of stibanate has been 
shown against L donovani. The encapsulation of sodium stibogluconate, a major front 
line drug for leishmaniasis, in tuftsin bearing liposomes demonstrated that efficacy of the 
drug was markedly increased against L. donovani infections in hamsters (Guru et al, 
1989). The improvement in the therapeutic efficacy of the liposomised drug may result 
from the respiratory burst-inducing activity of tuftsin, in addition to the effect of the 
targeted drug delivery of drug to the macrophages (Guru et al, 1989). The pretreatment of 
animals with free and liposomal tuftsin enhances their resistance to leishamania infection 
(Guru et al, 1989). The susceptibility of peritoneal macrophages from pre-treated animals 
to Leishmania infection was examined in vitro. The parasite multiplication inside such 
macrophages was considerably decreased, as compared to the macrophages of untreated 
animals (Guru et al, 1989). The resistance of the Parasite to antimonials is creating 
difficulty in management of leishmaniasis (Bryceson, 1987). The second front line drug 
Amp B is quite effective as an anti-leishmanial agent but it suffers from serious side 
effects. The toxic effects of Amp B can be minimized, keeping intact the antileishmanial 
property, by encapsulating this drug in the liposomes. The LD50 of Amp B was increased 
after liposomisation (Berman et al, 1986). The anti-leishmanial activity of Amp B is 
further enhanced when tuftsin was incorporated on the surface of Lip-Amp B liposomes 
(Guru et al, 1989). These results clearly indicate that Amp B in liposomes helps not only 
helps in reducing the drug toxicity but also increases the drug efficacy against L 
donovani infections. The Tuft-Lip-Amp B was more effective than Lip-Amp B against 
Leishamaniasis even at a low single dose of 0.5 mg/kg. The tissue distribution study 
demonstrates the higher and faster uptake of Tuft-Lip-Amp B liposomes from circulation 
with most of the liposomes being cleared from the circulation wdthin one hour after 
administration a.s compared to Lip-Amp B. 
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Vart IV 
TOPOSWE 
4.1 Historical development 
Podophyllotoxins have been used as active medicament by various cultures for over 
1,000 years (Table 5) (Slevin, 1991). In the 19"^  century, podophyllin was found to be 
topically effective for skin cancers. In 1946, the antimitotic properties of podophyllin 
were established (Liu et al, 1994). Clinical evaluation of podophyllotoxin and selected 
derivatives demonstrated modest antineoplastic activity. However, toxicity of 
podophyllin was prohibitive (Greenspan, 1950; Leiter, 1950). In the 1950s, investigators 
at Sandoz Pharmaceuticals began synthesising a series of podophyllotoxin derivatives in 
the hope of identifying agents, which retained antineoplastic activity, but had less 
toxicity. A series of aldehyde condensation products of the non-purified root of the Indian 
Podophyllum plant were found to have antitumour activity against LI210 leukaemia. 
After extensive isolation procedures, the most effective "antileukaemic factor' was found 
to be 40-demethylepipodophyllin benzylidene glucoside (DEPBG). Whilst previous 
antineoplastic Podophyllum compounds were spindle poisons which produced an 
increase in mitosis in fibroblast cultures, in tissue cultures treated with DEPBG mitotic 
figures were practically absent. Two analogues of DEPBG, with increased antineoplastic 
activity were subsequently synthesised, etoposide (VP-16) in 1966 and teniposide (VM-
26) in 1967. Remarkably, clinical testing of teniposide began within 2 years of drug 
synthesis (4 years for etoposide). Clinical trials begun in 1971 and first report that 
appeared in 1973-1974, demonstrated antineoplastic activity for etoposide and teniposide 
in AML (acute myeloid leukaemia), Hodgkin's disease, non-Hodgkin's lymphoma, lung 
cancer (both small cell and non-small cell), gastric cancer, breast cancer and ovarian 
cancer (Table 6: Vogelzang et al, 1982; Johnson et al, 1991; Radice et al, 1975; Aisner et 
al, 1991; Muggia et al. 1991; Ajani et al, 1991; Sledge et al, 1991; Fleming et al, 1989). 
In 1978, Sandoz licensed development of etoposide and teniposide to Bristol-Myers 
Squibb. With the demonstrated antineoplastic activity of the drug, FDA approval was 
granted for etoposide (VePesid) in 1983. It is interesting that at the time of approval, the 
mechanism of action of this drug and its pharmacology were only beginning to be 
defined. 
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4.2 Mechanism of action 
Studies in the late 1970s clearly demonstrated widespread antitumour activity for 
etoposide and led to FDA approval for clinical use. However, the mechanism by which 
etoposide exerts its antineoplastic effects remained unclear. Although etoposide, like 
other podophyllins, can alter microtubule assembly, it does so only at concentrations 
several fold greater than those achieved in vivo. Etoposide caused dose-dependent single-
strand and double strand DNA breaks when incubated with cells in culture (Loike et al, 
1976). When etoposide was removed, DNA breakage was quickly repaired. Incubation of 
etoposide with pimfied DNA did not produce DNA strand breaks. However, when 
etoposide and isolated nuclei were incubated, DNA strand breaks were seen (Wozniak ei 
al, 1983). Thus, something in the nuclei, in addition to DNA, was required to obtain 
DNA strand breakage. The relationship between topoisomerase II inhibition and 
etoposide's antitumour activity was, in part, delayed as information about this important 
enzyme was being elucidated. It was not until 1979 that the name 'DNA topoisomerases' 
was introduced (Liu et al, 1994). Extensive biochemical analysis of this group of 
enzymes was being undertaken at the same time etoposide was being brought to the 
clinic. In 1984, several laboratories demonstrated that mammalian topoisomerase II was 
the target for etoposide action. Topoisomerase II enzymes are multisubunit proteins, 
require ATP for overall catalytic activity and modulate DNA topology by passing an 
intact helix through a transient double-stranded break created in the DNA backbone (Liu 
et al 1994, Froelich-Ammon et al, 1995). As a result of their double-stranded DNA 
passage reaction, type II topoisomerases are able to regulate over- and under-winding of 
the double helix and resolve nucleic acid knots and tangles. Etoposide and other topo II 
inhibitors do not kill cells by blocking topoisomerase catalytic function. Rather they 
poison these enzymes by increasing the steady-state concentration of their covalent DNA 
cleavage complexes. This action converts topoisomerases into physiological toxins that 
introduce high levels of transient protein-associated breaks in the genome of treated cells. 
The potential lethality of these drug-induced cleavage complexes rises dramatically when 
replication machinery or helicases attempt to traverse the covalently bound 
topoisomerase roadblock in the DNA. This disrupts the cleavage complex and converts 
transient single- or double-strand breaks into permanent double-stranded fractures, which 
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are no longer held together by proteinaceous bridges. These breaks become targets for 
recombination, sister chromatid exchange, the generation of large insertions and deletions 
and the production of chromosomal aberrations and translocation. When these permanent 
DNA breaks are present at sufficient concentration, they trigger a series of events that 
ultimately culminates in cell death by apoptosis. 
4.3 Etoposide pharmacology 
The molecular weight of etoposide is 588. It is poorly soluble in water. To increase 
solubility, etoposide is formulated in vials containing lOOmg drug, 400 mg polysorbate 
80, 3.25mg polyethylene glycol 300, lOmg citric acid and absolute alcohol to 5 ml. 
Unopened vials are stable for 24 months at room temperature. Etoposide is most stable at 
pH 5. In basic solutions, it epimerizes to the cis-lactone. Because of its limited water 
solubility, etoposide has a tendency to precipitate when diluted for intravenous (i.v.) 
administration. Visual inspection of precipitate in solution is a sensitive measure of 
stability. When mixed in either 5% dextrose or 0.9% sodium chloride, the duration of 
etoposide stability is dependent on concentration. (Table. 7: Slevin, 1991). Undiluted 
etoposide has been reported to crack plastic infusion devices, probably due to the 
polyethylene glycol contained in the solution (Schwinghammer et al, 1988). Initial 
pharmacokinetic studies by P. Creaven and L. Allen (Creaven et al, 1975) involved 
administration of tritiated etoposide intravenously to patients. Subsequent thin-layer 
chromatography of blood and urine samples was performed to distinguish unchanged 
drug from metabolites. In these important studies, approximately 50% of the total dose of 
the radiolabel was recovered in the urine, with two-thirds of urinary radioactivity present 
as unchanged drug. These studies documented several key points about etoposide 
pharmacology, which have subsequently been confirmed in other studies (Slevin, 1991; 
Fleming et al, 1989; Hande, 1992). First, approximately one-third of administered 
etoposide is excreted in the urine. Etoposide clearance, in part, related to creatinine 
clearance (D'lncalci et al, 1986). Second, little of the drug is excreted into the bile. Third, 
hepatic metabolism (to glucuronide and demethylmetabolites) accounts for one-third of 
drug clearance. Creaven and Allen performed similar studies with teniposide and 
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demonstrated a longer drug half-life with this agent and more extensive biliary clearance 
when compared with etoposide (Creaven et al, 1997). 
Pharmacokinetic parameters determined from studies at Vanderbilt University are 
summarised in Table 8. Studies by other investigators have yielded similar results. The 
area under the concentration versus time curve (AUC) and peak plasma concentrations 
achieved following i.v. etoposide administration are linearly related to dose (Hande et al, 
1984). This linear dose-clearance relationship and the fact that myelosuppression is the 
primary dose-limiting etoposide toxicity, has made etoposide a popular component of 
high-dose, marrow-ablative chemotherapy regimens. Etoposide's steady-state volume of 
distribution ranges from 5 to 17 l/m2. Etoposide is highly bound to plasma proteins with 
an average free plasma fraction of 6%. Total etoposide clearance is modestly decreased in 
patients with renal failure, but not in patients with hepatic obstruction (Hande et al, 
1990). The etoposide plasma-binding ratio (the amount of bound drug/the amount of free 
drug) is directly related to the serum albumin concentration. Cancer patients, in particular 
those with hepatic involvement, often have reduced serum albumin concentrations. Since 
free drug is biologically active, conditions which decrease protein-binding increase the 
pharmacological effect of a given dose. Patients with low serum albumin concentration 
have greater toxicity from a given drug dose than patients with normal serum albumin 
concentrations. Several studies (Joe et al, 1996; Minami et al, 1996) have correlated 
plasma etoposide concentrations (or AUC) with toxicity. Measurement of free versus 
total drug provides better correlations. Correlations of drug concentration and tumour 
response have been suggested in some, but not all studies (Joel et al, 1996; Zucchetti et 
al, 1995). 
4.4 Schedule dependence of etoposide and oral etoposide 
Several preclinical findings suggested that the duration of exposure of neoplastic cells to 
etoposide is important in producing maximal antitumour activity (WolV et al, 1987; 
Drewinko et al, 1976). Etoposide's target, topoisomerase II, is signi^Ecantly expressed 
only in dividing cells during selected mitotic phases of the cell cycle (Heck et al, 1988). 
Chronic scheduling may, therefore, be advantageous because it maximises the likelihood 
of exposing malignant cells to etoposide during sensitive periods of the cell cycle. 
63 
Cytotoxicity of topoisomerase-II-targeting drugs relates not only to the magnitude of 
formation of drug-induced, enzyme mediated DNA strand breaks, but also to the 
intracellular half-life of these lesions (Fox et al, 1990). Therefore, antineoplastic agents 
or protracted scheduling schemes that prolong the presence of DNA strand breaks in the 
cell would be expected to result in superior efficacy. 
Although the importance of drug administration scheduling on etoposide's antineoplastic 
activity was suggested in early preclinical and clinical trials, the most informative study 
on the importance of schedule dependence included patients with small cell lung cancer 
(SCLC) who received 500 mg/m^ etoposide either as a 24-h i.v. infusion or as a daily 2-h 
infiision for 5 days (Slevin et al, 1989). Though both patient groups received the same 
total drug dose, differences in response rates were dramatic. 
In the 1-day treatment arm, 10% of patients responded to therapy, compared with an 89% 
response rate in the 5-day treatment arm. Pharmacokinetic data from this trial revealed no 
significant difference in total AUC measurements between these two treatment arms. 
However, prolonged maintenance of low serum etoposide concentrations (1 mg/ml) was 
associated with superior efficacy in the 5-day treatment arm. In a subsequent study in 
SCLC (Clark et al, 1994), five and eight day schedules were found to have equivalent 
antineoplastic activity. Haematological toxicity was greater in the 5-day arm. These two 
studies suggested that prolonged exposure to low concentrations of etoposide might 
improve etoposide's therapeutic ratio. 
In 1987, the US Food and Drug Administration approved a soft gelatin capsule 
formulation of etoposide for clinical use. This allowed long-term drug administration. 
Etoposide capsules contain 50mg etoposide in a solution of purified water, citric acid, 
glycerin and polyethylene glycol 400. The use of oral etoposide provides a convenient, 
tolerable treatment regimen that avoids the need for hospitalisation. There are, however, 
drawbacks to the use of oral etoposide. Once absorbed, there is no pharmacological 
difference between oral and i.v. etoposide with respect to mechanism of action drug, half-
life, mode of drug elimination or type of toxicity. Bioavailability of oral etoposide ranges 
from 40 to 75% and varies with drug dose. Oral absorption is linear to doses up to 250mg 
but decreases with doses greater than 300 mg (Hande et al, 1993). 
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Table 5 summarises a series of studies from Vanderbilt and compares the variability in 
apparent drug clearance as a function of the route of drug administration. Between-
patient variability is significantly greater than within-patient variability. 
However, administration of drug by the oral route increases variability both within and 
between patients as compared to intravenous administration. Joel and colleagues (Joel et 
al, 1995) have tried to improve the bioavailability and variability of etoposide by 
concomitant administration of ethanol, bile salts, cimetidine, metaclopromide and 
propantheline without success. Preclinical studies (Leu et al, 1995) suggest that inhibition 
of P-glycoprotein may improve etoposide bioavailability. To determine whether 
administration schedules longer than a standard 3-5 day treatment might further improve 
the therapeutic index of etoposide, prolonged oral dose-regimens have been developed 
(De Jong et al, 1995). Several phase II studies using either 50mg or 50 mg/m^ etoposide 
once or twice daily for 14-21 days have been undertaken involving patients with both 
previously treated and untreated lung cancer, lymphoma, previously treated germ cell 
tumours, soft tissue sarcomas, ovarian cancer, breast cancer, melanoma and renal cell 
carcinoma (Hande et al 1996). Responses have been seen in all tumour types, although 
uncommon in melanoma, sarcoma and renal cell carcinomas. Response rates are equal to 
or greater than those expected from historical data from similar patient populations. 
Several patients with SCLC, lymphomas and germ cell tumours who have responded to 
the chronic schedule were previously clinically resistant to standard doses and schedules. 
The activity of oral etoposide in these phase II trials suggested that prolonged oral 
etoposide administration might be a more effective method of drug administration. 
Unfortunately, two randomized clinical trials have now been conducted which have failed 
to demonstrate any benefit to prolonged oral etoposide therapy, at least in the initial 
treatment of SCLC. Both the Cancer and Leukemia Group B (CALGB) (Miller et al, 
1995;) and British Medical Research Council (Girling et al, 1996) trials, which compared 
long-duration oral etoposide with more standard chemotherapy, failed to show any 
improvement in response rates or median survival with oral etoposide administration 
when compared with more standard treatment regimens. 
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Fig. 1 Chemical structure of Etoposide 
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Table. 5: History of Podophyllotoxins in medicine 
Drug 
Wild 
Podophyllum 
Podophyllin resin 
Podophyllin 
Mandrake Root Issyk-Kul 
Carter's Little Liver Pills 
Podophyllin/Analogues 
Year 
900 
1800 
1820 
1861 
1940s 
1945 
1950 
Therapy 
Cancer 
Emetic, cathartic 
Scrofula, syphilis,cough 
Skin cancer 
Testicular cancer 
Everything 
Lymphoma 
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Table: 6 Antineoplastic activity of etoposide as a single agent 
Tumour 
Testicular 
Small cell lung cancer 
Untreated 
Previously treated 
Non-hodgkin's lymphoma 
Hodgkin's Disease 
Non-lymphocytic leukemia 
Ovarian 
Gastric 
Breast 
Untreated 
Previosly treated 
Non-small cell lung cancer 
Kaposci's sarcoma 
Response rate (%) 
33 
44 
13 
29 
14 
24 
21 
21 
15 
6 
10 
34 
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Table. 7: Etoposide stability in solution 
Concentration (jig/ml) 
0.2 
0.4 
0.5 
0.6 
0.75 
1.0 
Duration of stability (h) 
96 
72 
24 
18 
8 
5 
Table. 8: Etoposide pharmacokinetic parameters 
(Vanderbile data) 
Volume of distribution 
Clearance (plasma) 
Renal clearance 
Half life 
13.8± 7.41m' 
26.5± 9.6 ml/min m' 
9.3± 3.9 ml/min/m' 
6.4± 2.4 h 
69 
Table. 9: Variation in etoposide clearance with different routes of 
administration 
Group 
Within same patient 
Within same patient 
Between patients 
Between patients 
Administration 
i.v. 
p.o. 
i.v. 
p.o. 
Coefficient 
of variation % (n) 
11% 
16% 
29 
38% 
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1.1 Introduction 
It has been demonstrated that indiscriminate usage of chemotherapeutic agents may lead 
to development of other health related complications, for example, increased frequencies of 
bladder cancer have been demonstrated following cyclophosphamide therapy (lARC, 1981). 
Cyclophosphamide is an alkylating agent that can be intercalated within DNA base pairs upon its 
administration to the body. Increased incidence of chromosomal aberrations and sister chromatid 
exchanges were observed in peripheral blood lymphocytes and bone marrow cells of 
cyclophosphamide treated persons. Cyclophosphamide has been extensively tested to induce 
dominant lethal mutation, chromosomal aberration, mononuclei, sister chromatid exchanges and 
DNA damage in vivo. (lARC, 1987) 
Tuftsin is a naturally occurring tetrapeptide with the sequence (Thr-Lys-Pro-Arg), an 
integral component of immunoglobulin G and is released from its parent molecule by enzymatic 
cleavage (Najjar et al, 1970). Tuftsin has been shown to stimulate phagocytosis by human and 
animal polymorpohonuclear leukocytes and macrophages (Nishioka, 1979). It includes 
enhancement of the migration response of human mononuclear cells and augmentation of antigen 
specific, macrophages-dependent sensitization of T lymphocytes. Many reports have indicated 
that it prevents carcinogenesis (Najjar et al, 1980; Catane et al, 1981). In the present set of 
experiment, we demonstrated the antimutagenic effect of tuftsin against cyclophosphamide-
induced genotoxicity in bone marrow derived lymphocyte cells. Each animal was pretreated with 
50 ng of tuftsin (liposomised form) for three consecutive days followed by subsequent challenge 
with cyclophosphamide by intraperitoneal route (40 mg/kg). The extent of cyclophosphamide-
induced mutagenesis was determined by the incidence of chromosomal aberrations in animals 
with or without tuftsin pretreatment. The incidences of aberrant cells are expressed as percentage 
of damaged cells (aberrant metaphases) out of total number of cells. The result of the study 
demonstrated that pretreatment with tuftsin alleviate cyclophosphamide induced genotoxic 
manifestations as revealed by suppression of chromosomal aberration frequencies. Tuftsin also 
protects immune cells from toxic effects of cyclophosphamide by increasing their proliferation 
and minimizing chromosomal disorganization. 
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1.2 Materials and Methods 
1.2.1 Chemicals; 
Cholesterol, colchicines, cyclophosphamide, egg phosphatidyl choline, and other reagents 
used in the study were of the highest purity available. Cholesterol was bought from 
Centron Research Laboratory, Mumbai, INDIA and used after crystallizing it three times 
with methanol. Giemsa stain and colchicine were purchased from Sigma Chemical Co. 
Tuftsin was modified at C-Terminus by attaching a sufficiently long hydrocarbon fatty 
acyl residue to the C-terminus through an ethylenediamine spacer arm (Thr-Lys-Pro-Arg-
NH-(CH2)2-NH-CO-Ci5H3i), which permits almost quantitative incorporation into 
liposomes, following published procedure (Gupta et al, 1986). Glass double distilled 
water was used in all the experiments. 
1.2.2 Animals 
Female swiss albino mice 9 weeks of age and average body weight (b.w) of 18-20 gms 
were used in the study. They were randomly selected & housed in polycarbonate boxes 
with steel wire tops and rice husk bedding with free access to rodent diet. Experiments 
were conducted following mandates approved by the Animal Ethics Committee 
(Committee for the purpose of control and supervision of Experiments on Animals, Govt, 
of India). 
1.2.3 Treatments: 
The mice were administered with liposomised tuftsin at the dose of 50 ocg/animal/day for 
three consecutive days through intraperitoneal route. Cyclophosphmide was used as 
genotoxic agent and was given as intraperitoneal (i.p.) injection at single dose of 40 
mg/kg 24 hrs after the last dose of tuftsin on 4 day in the group (IV) of animals. The 
control group (II) received single dose of i.p injection of CP only. The negative control 
group (I) received single dose i.p injection 0.4 ml of normal saline only. Four treatment 
gps (of six animals each), were maintained as described below. 
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Group 
I 
11 
III 
IV 
Pre-treatment 
-
-
Tuftsin (50ocg/animal) 
Tuftsin (50ocg/animal) 
Treatment 
0.4 ml D.W. 
CP (40 mg/kg) 
-
CP(40mg/kg) 
1.2.4 Chromosomal analysis: 
After treatment, the animals fi:om various groups were sacrificed at the sampling time of 
48 hrs by cervical dislocation (colchicines was given at the dose of 2 mg/kg of the body 
weight, 2 hr prior to killing to arrest the metaphase stage). Cytogenetic analysis was 
performed as per protocol of Preston et al. The bone marrow was flushed out from both 
femurs using Hank's balanced salt solution (pH 7.2). The cells were centrifuged at 1000 
rpm for 5 min and the pellet was redispersed in hypotonic solution of 0.56% (w/v) KCl 
for 30 min at 37° C to permit osmotic swelling of cells. Swollen cells were fixed in ice 
cold fixative (Methanol 3: acetic acid glacial 1) dropped to slides and stained with 
phosphate buffered 5% Giemsa solution. 300 metaphase plates were selected randomly 
for screening 15-20 plates per animal. Frequencies of total chromosomal abnormalities, 
as well as separate frequencies of structural (chromatid breaks/ gaps/ring chromosomes) 
and mitosis disruption (clumping/stickiness) types were scored. 
The incidence of expressed cells was expressed as percentage of damaged cells (aberrant 
metaphases). 
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The suppression percentage of chromosomal aberrations was calculated as: 
100 . < 
Percent incidence of aberrant cells in tuftsin pretreated and 
Cyclophpsphamide post treated groups 
Percent incidence of aberration cells in CP alone treated group} 
~\ 
xlOO > 
J 
lA 
1.3 Results 
Tuftsin alleviates genotoxic manifestation induced by cyclophosphamide. 
The result of the study demonstrated that pretreatment with tuftsin alleviate 
cyclophosphamide induced genotoxic manifestations as revealed by suppression of 
chromosomal aberration fi'equencies. Cromosomal aberration frequencies were measured 
in terms of both structural changes (breaks, chromatid gap, deletion, ring, fusion, multiple 
breaks) and mitotic disruptional abnormalities (hypoploidy stickness, clumping, 
pulverization, polyploidy). Chromosomal analysis of animals pretreated with tuftsin 
showed suppression in the incidence of structural changes and mitosis disruption 
abnormalities. The percent of structural changes and mitotic disruption in chromosomes 
was found to be reduced to 3.77±0.19 and 4.77±0.19 respectively. While control group of 
animals, which were treated with CP alone caused a 5-6, fold increase in the incidence of 
total chromosomal aberration as well as structural changes and mitosis disruption 
abnormalities alone. The percent suppression in total chromosomal aberration induced 
by tuftsin in CP produced clastogenic damage was identified to be 59.73±9.44. The 
tuftsin treatment alone did not induce abnormalities and cannot be deemed clastogenic. 
(Table: 11) 
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Table. 11: Preventive effect of tuftsin pretreated on CP induce 
chromosomal aberration 
Group 
I 
II 
III 
IV 
Abnormalities scored (incidence of aberrant cells) 
Structural 
changes in 
chromosomes 
(%±S.D) 
2.21+0.5 
9.3310.88 
2.22+0.38 
3.7710.19 
Mitotic 
disruption 
(%±S.DE) 
2.110.17 
12.1010.69 
2.21+0.50 
4.7710.19 
Total 
(%1S.D) 
4.3210.57 
21.4411.54 
4.4410.84 
8.5311.17 
No. of 
aberration 
per cell 
0.0410.005 
0.2110.01 
0.0410.008 
0.08510.013 
Suppression 
(%+S.E) 
59.7319.44 
<ir 
^r07^i^^ 
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1.4 Discussion 
In the present study, tuftsin has been fcund to inhibit the incidence of cyclophosphamide 
induced chromosomal aberrations in mice, suggesting its potential as an antimutagenic 
agent. Considerable numbers of literature have documented antitumour and immuno 
stmulating functions of tuftsin (Najjar, 1970; Nishioka, 1979; Najjar et al, 1980; Catane 
et al, 1981). However this is the first report to establish its antimutagenic potential. 
Cyclophosphamide, a chemotherapeutic drug, damage chromosomes through generation 
of free radicals and alkylate DNA thereby producing mutagenicity (lARC, 1987). 
Our results clearly reveal that the frequency of different types of chromosomal 
aberrations induced by cyclophosphamide was found to be declined by the treatment of 
tuftsin (Table. 11). The chromosomal aberration was assessed on the basis both structural 
(breaks, chromatid gap, deletion, ring, ftision, multiple breaks) and disruption changes 
(hypoploidy stickness, clumping, pulverization, polyploidy). The structural changes were 
found to be reduced from 9.33% to 3.77% and ••• '• disruptional changes were reduced 
from 12.44%) to 4.77% on pretreatment with tuftsin upon subsequent treatment with 
cyclophosphamide. The overall suppression in chromosomal aberration was found to be 
59.77%) in tuftsin treated animals. Total chromosomal aberration was found to be reduced 
from 21.44% to 8.53%. However in animals, which were not pretreated with tuftsin the 
chromosomal aberration was found to be enhanced from 4.32%) to 21.44%) upon exposure 
with cyclophosphamide. These results indicate that pretreatment with tuftsin can 
effectively check the incidence, multiple aberrations induced by cyclophosphamide. 
Since mutation induced at cytogenetic level are probable cause of cancer and fact that 
tuftsin has property of both antimutagenic and antitumorogenic suggest that tuftsin can be 
exploited in both prophylactic and therapeutic intervention against cancer. 
On the basis of present findings we can conclude that tuftsin possess strong 
antimutagenic potential in cyclophosphamide induced chromosomal aberration. However 
mechanism of antimutagenicity of tuftsin needs to be explored in order to understand 
chemo preventive effect. 
It is premature to comment upon the possible mode of action executed by tetrapeptide as 
tuftsin. However beside macrophages, its antimutagenic effect seems to involve other 
cells as well. It has been reported that treatment with cyclophosphamide induce depletion 
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of neutrophils as well as PBMCs (Masood et al, 2004). This indirectly suggests that 
beside neutrophils/PBMCs observed antitumor effect of tuftsin is mediated by some 
nonspecific cells such as NK cells. Nevertheless, involvement of immunomodulators 
such as tuftsin for elimination of cancerous (cells with unnatural phenotype) seems to 
offer a novel strategy that can be exploited for treatment of cancer ailments: In this 
regard, combination of tuftsin and some potent tumoricidal agents may prove to exert less 
toxic manifestation as well as improved therapeutic index. 
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chapter 2 
NTITUMOnOC^Emc 
EEffECT Of TUFTSIN 
2.1 Introduction 
Tuftsin, a tetra peptide is known to bind specifically to macrophages, monocytes and 
PMN leukocytes and possess broad spectrum of immunomodulatory activities. Moreover, 
many workers have reported the anti-tumor activity of tuftsin against experimental tumor 
models as well (Nishioka et al, 1981; Nishioka et al, 1983). Florentin et al stated that 
tuftsin is able to potentiate various types of immune response when injected into mice, 
and can be used as a potent activator of macrophages in cancer therapy (Florentin et al, 
1978). It was also stated that tuftsin significantly increases survival rates among Rauscher 
virus leukemia infected mice and demonstrates antitumor activity against murine 
melanoma in vivo (Knyszynski et al, 1983; Noyes et al, 1981). In the present study we 
evaluated antitumorogenic potential of tuftsin against soft tissue sarcoma developed by 
carcinogen Benzo (a) pyrene (250^g/animal) in swiss mice (Faderbe et al, 1992b). 
Benzo (a) Pyrene is a polcyclic aromatic hydrocarbon (PAH) that is metabolically 
activated in cells by cytochrome P450 enzymes and/or peroxidases to reactive 
intermediate that damage DNA. One pathway of activation forms dihydrodiol epoxides 
that covalently bind to exocyclic amino group of purines in DNA to form stable adducts. 
Another pathway involves formation of radical cations that bind to the N7 or N8 of 
purines to form unstable adducts that purinate to leave apurinic (AP) sites in DNA. 
Polycyclic aromatic hydrocarbons (PAHs) induce tumor formation in many tissues in 
rodents. Environmental mixtures of PAHs have been implicated for tumour induction in 
humans as well (Cavalieri et al, 1991; Grimmer et al, 1983; Harvey et al, 1991; LaVoie 
et al, 1993). Tumor induction in mouse skin has been extensively used to determine the 
carcinogenic potency of individual PAHs (Cavalieri et al, 1991; LaVoie et al, 1993; 
DiGiovanni et al. 1992; Higginbotham et al, 1993; DuBowski et al, 1998). The 
development of tumor was ascertained by histopathological examination of the tissues, 
which was further confirmed by microscopic examination. The tumor bearing animals 
were treated with various liposomal formulation of etoposide in combination with 
immunomodulator tuftsin. The animals were treated with free, liposomised (without 
tuftsin) and tuftsin bearing liposomised preparation of anticancer drug. Drug formulations 
were administered by intravenous route for five consecutive days. The efficacy of various 
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formulations was ascertained on the basis of survival of the treated animals as well as 
histopathological studies. To perform histopathological studies, mice were sacrificed by 
cervical dislocation and fixed in 10% formaldehyde solution. Among various 
formulations tuftsin bearing liposomised drug was found to be most effective. 
2.2 Materials and Methods 
2.2.1 Chemicals 
Benzo (a) Pyrene (98%) purity and etoposide were ptirchased from Sigma Chemical Co. 
2.2.2 Animals 
Female Balb/C mice of weight 18 ± 2 g were used in the whole study. The animals were 
given a standard pellet diet (Hindustan Lever Ltd.) and water ad libitum. Animals were 
checked daily for their mortality and morbidity prior to commencement of the study and 
only healthy animals were included in the experiment. The techniques used for bleeding, 
injection as well as sacrifice of animals were strictly performed following mandates 
approved by the Animal Ethics Committee (Committee for the purpose of control and 
supervision of Experiments on Animals, Govt, of India). 
2.2.3 Tumour Development 
Tumor was developed (Fig. 2) by subcutaneous administration of single dose of Benzo 
(a) pyrene (250(ig/animal) according to published procedure (Faderbe et. al, 1992b). 
2.2.4 Isolation of PC 
Egg PC was isolated and purified following the published procedure (carefully, and 
washed with acetone (100 ml) in a mixer 5-6 times to get rid off the colored impurities 
Singleton et al, 1965). Briefly, egg yolks of one dozen eggs were separated. The resulting 
white solid was powdered and dried in vacuum for 30 minutes to remove traces of the 
solvent. The extraction was performed by stirring the solid mass with one liter of absolute 
alcohol for 2-3 hours. After filtration, the residue was re-extracted with another 500-ml. 
of ethanol. The filtrates were mixed and evaporated off at 40-45 "C. The sticky mass thus 
obtained was dried under high vacuum to remove traces of the solvent, dissolved in 
minimum amount of petroleum ether (b.p.60-80 *^C ) and poured onto chilled acetone to 
obtain a white sticky precipitate. The solvent from the precipitated material was removed 
by decantation. The sticky solid precipitate was redissolved in petroleum ether and again 
poured onto the chilled acetone. The process was repeated 2-3 times to obtain crude PC. 
For further purification, it was chromatographed on a neutral alumina (grade III) column. 
The elution was performed using increasing amount of methanol in chloroform. Fractions 
obtained with 5-7% methanol in chloroform corresponded to pure PC. It was further 
purified by chromatography over Sephadex LH-20 column (2.5x 100 cm), using 
chloroform/methanol (1:1 v/v) as the eluant. The elution rate was maintained at 60-70 ml 
per hour. Two-ml. fractions were collected and checked for the presence of pure PC. The 
purity was ascertained by thin layer chromatography using silica gel G-60 TLC plates. 
The plates were developed using chloroform/methanoI/water (65:25:4) as the solvent 
system, and stained with iodine vapor followed by molybdenum-blue spray to visualize 
various phospholipid spots (Dittmer and Lester, 1964). 
1.2.5 Liposome Preparation 
Unilamellar liposomes of etoposide were prepared from egg PC (49 |j,mol) and 
cholesterol (21 i^ mol) with or without tuftsin (7-8% by PC weight) following published 
procedure (Owais et al, 1993). Briefly, the mixture of lipids and etoposide (in ratio of 
40:1 w/w) along with tuftsin was dissolved in methanol and chloroform. The mixture of 
various lipids, etoposide and tuftsin was reduced to a thin dry film, in acid clean glass 
tube. Finally, the traces of the organic solvents were removed by subjecting the flask to 
vacuum overnight at 4 °C. The dried lipid film was hydrated with 150-mM sterile saline, 
followed by sonication for 1 hour at 4° C under N2 atmosphere in bath type sonicator. 
The sonicated preparation was centrifuged at 10,000 g for 1 h at 4 °C to remove un-
dispersed lipid and extensively dialysed against saline for 24 hour at 4 °C in the dark to 
separate free tuftsin from the liposomal preparations of tuftsin. The tuftsin bearing 
liposomal preparation was found out to be of unilamellar type with size range of 80 ± 10 
nm as revealed by electron microscopy. 
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1.2.6 Estimation of liposome intercalated etoposide 
The intercalation efficiency of etoposide in the liposomes was estimated 
spectrophotometrically as well as by HPLC method. In UV spectrophotometric 
determination of the etoposide a standard curve of the drug was plotted at 254 nm. The 
amount of drug associated with the liposome was determined by dissolving an aliquot of 
liposomal formulation in methanol and determining the absorbance at 254 nm against a 
corresponding amount of lipid in methanol as a blank (Canal et. al, 1986) with slight 
modifications. The amount of etoposide entrapped in liposomes was calculated from the 
standard curve of the drug solution. The intercalation efficiency of etoposide in 
liposomes was also estimated by HPLC method as well. The sample (20 \x\) was injected 
onto a Hypersil octyldecyl-silane 5 jLim particle size analytical colunm (150 by 4.6 mm 
[internal diameter]). Detection was accomplished with a UV-visible-light detector set at 
254 nm. A standard curve of etoposide was plotted by calibrating peak area versus 
amount of the drug injected into column. The elution buffer was consisting of an 
isocratic mixture of 0.005 M EDTA and methanol (2: 8 v/v). The flow rate was kept 1.2 
ml/min and retention time was found out to be 4.5 min. The intercalation efficiency of 
etoposide in both plain egg PC and tuftsin bearing liposomes was found out to be of the 
same order as estimated by spectrophotometric method (90 ± 4 percent). 
1.2.7 Estimation of liposome intercalated tuftsin 
The tuftsin entrapped in the drug containing liposomes was estimated by BCA method as 
modified in our lab (Owais et al, 2000). Briefly, the liposomes (given volume) were lysed 
with 10% Triton X-100 solution (the final concentration of Triton X-100 was maintained 
1%). For the estimation of tuftsin content, the mixture of solutions A and B of BCA 
reagent was added to an aliquot of tuftsin-incorporated liposomes digested with Triton X-
100. The reaction mixture was incubated at 37°C for 45 min. The absorbance was 
measured at 600 nm and the content of tuftsin associated with liposomes was determined 
using a standard curve of tuftsin plotted in the presence of Triton X-100. The 
incorporated tuftsin was found out to be about 98% tuftsin containing liposomes. 
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1.2.8 Treatment Schedule 
Chemotherapy was started when the tumour reached 200 mm .^ The animals were treated 
with free, liposomised (without tuftsin) and tuftsin bearing Hposomised preparation of 
anticancer drug 10 mg/m /day. Drug formulations were administered by intravenous 
route for five consecutive days. 
1.2.9 Histopathological examinations 
To assess the anticancer effect of these preparations mice were sacrificed by cervical 
dislocation and fixed in 10% formaldehyde solution. Subsequently tumor tissues were 
prepared using conventional paraffin sections and hemotoxylin-eosin staining. 
1.3 Results 
1.3.1 Tuftsin reduces tumor growth by specifically killing cancerous cells 
Among various formulations tuftsin bearing liposomised etoposide was found to be most 
effective as compared to liposomised etoposide and free drug against soft tissue sarcoma 
as revealed from histopathological examination of the tissue. The photograph obtained 
after histopathological examination of animals of different groups clearly showed that— 
1. Tuftsin associated liposomised drug revealed best therapeutic response in terms of 
reduction of hemorrhage, adipose connective tissue, foci of necrosis and density 
of sarcomatous cells. Cellular debris and presence of inflammatory cells were also 
observed. (Fig: 7). 
2. Liposomised drug (etoposide) treated animals showed better response in terms of 
reduction of hemorrhage, foci of necrosis and density of sarcomatous cells. 
Cellular debris and presence of inflammatory cells were also obvious. (Fig: 6) 
3. Free drug (etoposide) treated animals showed features of sarcoma with mild 
response after treatment in the form of reduced vascularity, zones of necrosis as 
well as infiltration by some inflammatory cells. (Fig: 5) 
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4. Control animals showed well developed soft tissue sarcoma with increased 
vascularization large pleomorphic, hyperchromatic spindle shaped cells with 
anisonucleosis and irregularly dispersed chromatin.(Fig: 3, 4) 
1.3.2. Tuftsin enhances the survival rate of treated animals 
Tuftsin bearing liposomised drug (Etoposide) was found to be most effective as 
compared to liposomised drug without tuftsin and free drug as revealed from enhanced 
survival rate. Our survival data in Fig: 8 clearly shows that 
1. All the animals in control group died within 15-30 days. 
2. There was significant enhancement in life span of free etoposide treated animals 
and median survival was found to between 35-65 days. 
3. Liposomised drug (etoposide) further prolonged the life span as animals treated 
with this formulation survived for longer duration and median survival was found 
to be > 60-90 days. 
4. Tuftsin bearing liposomised etoposide was found to best formulation as it was 
able to significantly enhance the survival and median survival in this group was 
found to be between > 100-120 days. 
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Fig. 2: Photographs showing well developed tumor. Large 
encapsulated and lobulated subcutaneous mass which is not 
adhered to the skin and intestine. Zone of hemorrhage is marl^ ed 
by dark spot. 
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Fig. 3: Photomicrograph from tumor showing zone of necrosis, 
increased vascularization and hemorrhage. Large number of 
hyperchromatic mesenchymal cells with features of soft tissue 
sarcoma are present. Some hyperchromatic ceils are also 
arranged in glandular form. H&E, X200 
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Fig. 4: Photomicrograph from tumor showing soft tissue 
sarcoma. It shows large pleomorphic, hyperchromatic spindle 
shaped cells with anisonucleosis and irregularly dispersed 
chromatin. Some inflammatory cells are also seen. H&E, X400 
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Fig. 5: Photomicrograph of tumor after treatment with free form 
of anti-cancer drug. It shows features of sarcoma with mild 
response after treatment In the form of reduced vascularity, 
zones of necrosis as well as infiltration by some inflammatory 
cells. H&E, X100 
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Fig. 6. Photomicrograph of tumor after treatment with 
liposomised drug, it shows better response in terms of 
reduction in hemorrhage, foci of necrosis and density of 
sarcomatous cells. Cellular debris and presence of inflammatory 
ceils are also obvious. H&E, X200 
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Fig. 7: Photomicrograph of tumor after treatment with Tuftsin 
associated liposomised drug. It reveals best therapeutic 
response in terms of marked reduction in sarcomatous cells, 
vascularity and hemorrhage. Appearance of large number of 
inflammatory cells and adipose connective tissue are also seen. 
H&E, X200 
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Fig. 8: Survival rate of animals treated with various formulations against 
soft tissue sarcoma 
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1.4 Discussion 
Etoposide is an antineoplastic agent, which acts by forming a ternary complex with 
topoisomerase II and DNA, causing DNA breaks and cell death (Hande, 1998). It is part 
of the first line therapy for small cell lung carcinoma (Smith et al, 1989) and drug-
resistant testicular cancer (Williams et al, 1987). However, strong lipophilicity is a major 
limitation in the administration of etoposide (Hande, 1992) and vehicles needed as 
solubilizers have often been associated wdth adverse effects such as hypotension, 
anaphylaxis, bronchospasm, etc. (O'Dwyer and Weiss, 1984). Etoposide also causes dose 
limiting haematological toxicity (Sinkule, 1984). Keeping into consideration, such 
intrinsic demerits that can hamper frequent use of etoposide, it is worst to develop a safer 
formulation with least toxic manifestations. Incidentally, higher lipophilicity offers better 
intercalation of drugs in lipid based formulations such as liposomes. Certain agents have 
been sho^vn to posssess activity to normalize or modulate pathophysiological processes 
and are hence called imunomodulatory agents (Wagner, 1983). Immunomodulators are 
biological response modifiers; exert their antitumor effects by improving host defense 
mechanisms against the tumor. They have a direct anti-proliferative effect on tumor cells 
and also enhance the ability of the host to tolerate damage by toxic chemicals that may be 
used to destroy the cancer. Immunomodulatory therapy could provide an alternative to 
conventional chemotherapy for a variety of diseased conditions, especially when host's 
defense mechanisms have to be activated under the conditions of impaired immune 
responsiveness or when a selective immunosuppression has to be induced in situations, 
like inflammatory diseases, auto-immune disorders, and organ/bone marrow 
transplantation (Upadhyay, 1997). 
Macrophages play an important role in non-specific and specific immune responses, as 
regulators of phagocytic and inflammatory functions. In addition to cell-to-cell 
interactions, macrophages also influence the immune system by secretion of cytokine 
functions in both autocrine and paracrine manner to protect host. 
In the present study we evaluated combination of immunomodulator tuftsin and 
etoposide in elimination of cancer developed in model animals. Antitumour activity of 
tuftsin has been known since long however no literature to date has evaluated its 
therapeutic potential in combination with etoposide. Since etoposide has cytotoxic 
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properties and the immunomodulator tuftsin possesses both anti tumor and 
immunomodulatory properties to co-activate immune system we considered it of interest 
to evaluate therapeutic potential of the combination of the two against experimental soft 
tissue sarcoma. Our results are well in agreement with proposed hypothesis as novel 
formulation of liposomised etoposide with tuftsin grafted on the surface was found to be 
more effective than fi-ee form, as shown by histopathological examinations of tissues 
which shows that animals treated with tuftsin bearing liposome have reduced growth with 
no obvious hemorrhage and minimal necrosis factor. Moreover, effective tumour 
regression was found in the animals treated with this formulation. The survival data 
ftirther substantiate antitumor potential of tuftsin bearing etoposide liposome as animals 
treated with this formulation survived for long duration. Almost 80% of animals survived 
for > 120 days post treatment. Enhanced efficacy of tuftsin bearing liposomes may be due 
to the fact that it will help in specific targeting of etoposide bearing liposomes to 
macrophages that will subsequently infiltered to tumor site. Free etoposide was not much 
effective as it was not able to gain access to cancer tissues and thus fewer molecules of 
active drug molecules were available for tumorocidal activity. Finally, we conclude that 
tuftsin bearing lipsomised etoposide is effective formulation against soft tissue sarcoma 
and pave way for treatment of other forms of cancer as well. Moreover formulation of 
tuftsin liposomes in combination of other anticancer drugs may be equally effective 
against various form of cancer. 
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